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The pandemic spread of HIV started almost 30 years ago and has claimed the lives of sev-
eral million people since then. The virus attacks the immune system of its host. Untreated,
the HIV infection leads to drastic opportunistic diseases, advancing to AIDS after a few
years. At this stage, the immune system is severely damaged and causes the decease of
the infected person. Fortunately, the number of new infections per year decreases thanks
to extensive HIV/AIDS-awareness campaigns and potent treatment regimen. Whilst to
date no vaccination or cure for an HIV infection has been found, there exist antiviral treat-
ments, which allow infected people to reach a close to normal life expectancy.
Still, the pandemic can not be eradicated, with annually new infections world wide run-
ning into millions, especially in developing countries [1]. The reason is, on the one hand,
lacking HIV education, hence renouncing of prevention, and on the other hand, unavail-
able treatment options. Also in developed countries the virus continues to spread, despite
of pervasive awareness- and treatment programs. The highest risk of further transmission
is early after infection [2]. This can be explained with the elevated virus load in the hu-
man body in the early (acute) phase after transmission, in combination with the initial
unawareness of the own infection.
Usually, medication lowers the risk of viral transmission [3]. However, HIV is a rapidly
mutating virus with a fast replication cycle, which allows it to quickly adapt to selective
pressure. This entails the development of resistant mutations, leading to reduced or no
effect of an antiviral drug. The combination of drugs needs to be changed accordingly, to
prevent treatment failure.
The situation gets critical, if multi-drug resistances occur and hardly any drug combina-
tion is working. Yet, mutational pathways of reaching resistant mutations include bot-
tlenecks and can only be acquired with a certain genomic background [4]. It remains an
ongoing challenge to learn more about the constraints for the virus to develop drug resis-
tance.
The currently available antiviral drugs target different processes of the HIV life cycle by
binding to crucial enzymes, and other involved proteins, or by competing with nucleo-
sides to stop the reverse transcription process [5]. Recently, new therapeutic strategies
are advancing: Despite the encoding for essential proteins, RNAs comprise a multitude
of regulatory elements and functional structures controlling virtually all biological pro-
cesses. Hence, regulating motifs in RNAs are promising drug targets, and first achieve-
ments in this direction have been attained [6, 7]. Nevertheless, processes of the regulatory
mechanisms in the HIV life cycle, as well as detailed structural information of the RNA
are still underexplored.
In this work, we present methods for the qualitative and quantitative inference of evolu-
tionary constraints, including the Mutational Intereference Mapping Experiment (MIME)
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[8] and direct coupling analysis (DCA) [9, 10]. Based on the former, we provide the soft-
ware MIMEAnTo to predict functional elements in RNA, published in [11]. Furthermore,
results of the adaption of the MIME framework to in cell experiments are presented, which
we published in [12]. We determined regulatory motifs in the 5′ UTR of HIV-1, which are
essential for viral RNA production in cells, as well as the packaging process of nascent
virions, respectively. Lastly, we attempt to improve the prediction of functional regions
with MIME by incorporating methods used in DCA. We set up a benchmark with dif-
ferent scenarios of mutational effects (disrupting function) including pairwise epistasis
(evolutionary constraints), and could indeed see improvements for a number of cases.
Yet, these are preliminary results, which encourage us to further address the approach in
more detail.
1.2 Structure of the Thesis
Foremost, in Chapter 2, we introduce the current knowledge regarding HIV biology, treat-
ment, and epidemiology to highlight the importance of ongoing HIV research. The subse-
quent Chapter 2 provides definitions of fitness, evolution, and evolutionary constraints.
With this background, we describe state of the art methods to infer epistasis and evolu-
tionary constraints in multiple sequence alignments in Chapter 4, with focus on direct
coupling analysis (DCA). The following Chapter 5 covers a method to identify and quan-
tify the commitment of positions within a functional sequence: the Mutational Interfer-
ence Mapping Experiment (MIME). Based on this method, we present our implementa-
tion of the MIME data analysis in Chapter 6, and an adaption of the MIME framework
for in cell experiments in Chapter 7. We introduce an approach combining MIME with
DCA related methods in Chapter 8, with the aim to improve the prediction of mutational
effects. The presented work is discussed in a conclusive summary in Chapter 9, including
an outlook for future aspects.
3Chapter 2
Background: HIV
In this chapter, we give an introduction of HIV and its biological background. First we
explore a short timeline since its suspected origin until today and the classification of
HIV strains. We look into more detail of the virus biology, including structure, genome
organisation, and replication cycle, and present different treatment strategies.
2.1 A short History Timeline of HIV
It is known that the human immunodeficiency virus (HIV) has its origin in Africa and
emerged by several independent cross-species transmissions of the Simian Immunodefi-
ciency Virus (SIV) from primates to humans [13]. In 1999, Gao et al. [14] found an SIV
strain in chimpanzees (SIVcpz) which was almost identical to HIV-1 and concluded that
the virus may have been transmitted from chimps to humans. They also discovered that
the transmittable and human infecting SIVcpz strain evolved by the junction of two dif-
ferent SIV strains, obtained by two different smaller monkey species eaten by the chim-
panzees [15].
There are different theories of how the zoonotic transmission happened. The most com-
monly accepted explanation is the hunting theory: The virus could be transmitted through
blood contact when the chimpanzees were hunted, killed and eaten, or kept as pets [13].
Normally, SIV would have been fought by the human immune system, but on a few oc-
casions the virus adapted itself within its new host and evolved to HIV-1 [16]. Latest
research results suggest that the virus crossed species from chimpanzees to humans in
Kinshasa, the Democratic Republic of Congo, in the 1920s [17].
HIV and AIDS remained unknown until the early 1980s, as infections happen unper-
ceivedly and without any symptoms. The virus quietly und unnoticedly reached differ-
ent continents (North America, South America, Europe, Africa, and Australia) [16]. Al-
though few cases of AIDS were retrospectively documented before, current data suggest
that an epidemic spread started in the 1970s [16]. In the beginning of the 1980s the virus
finally caught widespread medical awareness: Several cases of serious diseases, such as
a rare lung infection called Pneumocystis carinii pneumonia (PCP), severe immune de-
ficiency, and unusually aggressive cancer (Kaposi’s Sarcoma), of previously healthy pa-
tients were linked and clustered, described by various names in different parts of the
world [18, 19]. The unexplained cases were often connected to homosexual communities,
and hence corresponding names emerged, including GRIDS (gay-related immunodefi-
ciency syndrome), "gay cancer", etc. In September 1982, the Centers for Disease Control
(CDC) in the USA introduced the term AIDS (Acquired Immune Deficiency Syndrome)
for the first time, describing it as a disease causing a defect in cell mediated immunity and
other opportunistic infections [20]. Soon the disease turned out to affect all people from
all communities. Increasing evidence revealed that it is not only a sexually transmitted
disease, but can also be forwarded by shared needles among drug users, contaminated
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blood contact, and transmission from an infected mother to her child [16, 21–23].
In May 1983, the Pasteur Institute in France discovered a new retrovirus called Lymph-
adenopathy-Associated Virus (LAV), that was susptected to be the cause of AIDS [24].
Also the National Cancer Institute announced that they found a retrovirus related to AIDS
one year later, calling it Human T-Cell Lymphotropic Virus (HTLV)-3 [25]. At a joint con-
ference, they clarified that the two viruses are identical [26]. The International Committee
on the Taxonomy of Viruses agreed in May 1986 on the official name Human Immunod-
eficiency Virus (HIV) instead of HTLV-3/LAV [27].
In 1986, a second type of the virus has been found in West Africa [28]: The rare and not
pandemic strain of HIV-2 was found to be closely related to an SIV strain appearing in
sooty mangabeys.
Since the start of the pandemic, HIV has infected globally an estimated number of 77.3
million people and around 35.4 million people died from AIDS [1]. Fortunately, the an-
nual number of AIDS related deaths decreased since the peak in 2004 (1.9 million) by 51%
(940K deaths in 2017) [1]. Today, estimated 36.9 million people are living with an HIV
infection, yet, with a decreasing number of new infections every year [1].
2.2 HIV Classification
HIV belongs to the family of Retroviridae and is associated to the group of Lentiviruses [29,
30]. Retroviruses have genomic RNA, which is reverse transcribed into DNA and inserted
into the host’s DNA to be replicated [31]. Lentiviruses are causing slowly progressing,
chronical degenerative diseases [30].
HIV infects primarily vital CD4+ T cells in humans, helper cells of the immune system,
which will be destroyed by various mechanisms. The decline of CD4+ T cells to a critical
level leads to failure of the cell-mediated immune system. This advance phase of HIV
infection allows for the development of opportunistic infections and tumors that rarely
affect people who have a functioning immune system [32]. This late stage of symptoms
is referred to as acquired immunodeficiency syndrome (AIDS). However, antiretroviral
treatment (ART) allows many patients to live with an HIV infection without advancing to
AIDS.
Besides the CD4+ T cells, HIV infects macrophages [33], and dendritic cells[34].
FIGURE 2.1: Types and strains of HIV.
There are two types of HIV, characterised
on the basis of genetic differences and its
suspected pandemic origin: HIV-1, which
is the most common type affecting around
95% of the infected population, and HIV-2,
which is mainly found in regions of West
Africa and is less virulent and infective
than HIV-1 [13, 35]. HIV-1 and HIV-2 are
genetically different by 55% [35]. Hence,
not all detection tests for one of the types
are reliable for the other one [35, 36]. Both types can be classified into distinct groups and
subtypes on the basis of differences in the envelope region (cf. Section 2.3.1). This indi-
cates that each group arose out of independent SIV transmission events from non-human
primates to humans [13].
The predominant type HIV-1 comprises the following groups: Group M is the oldest, "ma-
jor" strain and responsible for the majority of the global HIV pandemic. The other groups
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O ("outlier"), N ("non-M or O"), and P (reported in 2009) are very rarely spotted in West-
Central Africa and Cameroon repsectively [13]. Group M diversified into nine subtypes
(A-D, F-H, J, K) and more than 40 different circulating recombinant forms (CRFs), based
on differences in the whole genome (see Figure 2.1).
Subtype B accounts only for 12% of the world wide HIV epidemic, but is prevalent in
the western countries (America, Western Europe, Australia). This fact explains why most
of the clinical research for HIV and available treatments were developed against subtype
B, although subtype C dominates with almost 50% of all infected people, most prevalent
in Southern Africa and India [13]. Studies suggest that some of the subtypes are more
virulent than others and might carry resistance against different treatments [36]. Still, an-
tiretroviral drugs (ARV) showed efficacy on different kinds of subtypes, altough mainly
developed for subtype B [37].
2.3 Virus Structure
One HIV virion measures a diameter of approximately 100 to 130 nm in its immature
and 130 to 145 nm in its mature state respectively [38–40]. Only mature virions, i.e. all
structural components are assembled, are able to infect new cells [41]. In Figure 2.2a the
structure of the mature virion is shown.
(A) Structure of HIV-1 virion (B) Capsid of HIV-1 virion
FIGURE 2.2: A: Structure of a mature HIV-1 virion. Graphic taken
from [42].B: Structure of the capsid of HIV-1, which is composed of viral
capsid proteins (p24). Graphic taken from [43].
The outer membrane or envelope of the virus is composed of a lipid bilayer originating
from a infected host cell, acquired during the budding process (cf. Section 2.4.5). The sur-
face is studded with viral envelope proteins (Env). Each consist of three transmembrane
glycoproteins (gp41) with surface proteins gp120 [44, 45], allowing the virus to attach and
fuse with target cells (cf. Section 2.4.1).
The envelope is surrounding a symmetrical matrix of viral structural proteins (p17), which
build the inner membrane of the virus particle [46].
The conical capsid, which is typical for retroviruses, is composed of viral capsid proteins
(p24) [47]. A close up is shown in Figure 2.2b. The capsid encloses the viral genome, two
copies of the positive sense genomic RNA (gRNA), which are tightly attached to nucleo-
capsid proteins (p7). Furthermore, the capsid encompasses the essential enzymes reverse
transcriptase and integrase [44].
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2.3.1 Genome Organisation and Structure
The genome of HIV consists of two identical single stranded RNA molecules of roughly
10,000 nucleotides. Each of the sequences contains nine open reading frames (ORF) en-
coding 15 (16 for HIV-2) proteins and several structural elements, depicted in Figure 2.3.
FIGURE 2.3: Genome organisation in HIV-1 on the three reading frames.
Figure taken from [42].
Structural Proteins
The three polyproteins Gag, Pol and Env encoded by their respecitve genes are common
for all retroviruses [48].
The gag and env genes encode structural components of the viral particle: The precursor
Gag protein p55 is important for the viral assembly at the plasma membrane, hence its
name assemblin. It is processed by the viral protease into four capsid proteins, namely
matrix (MA/p17), capsid (CA/p24), nucleocapsid (NC/p7) and p6 protein, which form
the core of the virion, as explained above [49]. The env gene encodes the glycoprotein
gp160. Cleavage of this precursor results in two components for the outer membrane en-
velope, the surface protein (gp120) and transmembrane protein (gp41).
Enzymes and Gene Regulating Proteins
The pol region provides three essential enzymes: protease (PR), reverse transcriptase
(RT), and integrase (IN), products of the protease processed Gag-Pol precursor protein [48,
49].
The proteins Tat and Rev are essential gene regulating factors. The tat gene comprises
transcriptional transactivators p14 and p16, facilitating the HIV gene expression by bind-
ing to the TAR element in the 5′ long terminal repeat (LTR) [49]. The rev gene expresses
a phosphoprotein, the regulator of expression of viral proteins, promoting the nuclear ex-
port of the viral RNA to the cytoplasm by binding to the Rev response element (RRE) [48,
49].
Accessory Proteins
The expressed proteins beyond these essential structural and regulatory proteins and en-
zymes are called accessory proteins. They are not necessary for viral propagation, but
appear to be conserved in different strains. The genes vif , vpr, and nef are found in
all HIV and SIV strains, whereas vpu is unique for HIV-1 and a few closely related SIV
strains. A duplication of the vpr gene resulted in the emergence of an additional gene in
HIV-2 and few SIV types [49], vpx.
Vif encodes the viral infectivity factor, i.e. it is promoting the infectivity of the virus. The
viral protein R (Vpr) is found inside the nucleus of the virion and targets different reg-
ulatory functions, e.g. the import of pre-integration complexes, the induction of cellular
differentiation, or cell growth arrest. The viral protein U (Vpu) plays a role in degradation
of CD4 in the endoplasmic reticulum, and the release of virus particles from the plasma
membrane of HIV-1 infected cells [49]. The nef (negative factor) gene, located within the
3′ LTR, is one of the first genes to be expressed within primate lentivirus infected cells and
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an important virulence factor in vivo, however dispensable in vitro [49]. The Vpr homo-
logue Vpx in HIV-2 also improves the efficiency of lentiviral infection by influencing the
replication of the virus.
In addition to genes encoding for the above described proteins, the viral genome occupies
non-coding regions comprising various structural and functional elements that interact in
complex ways to modulate gene expression.
After reverse transcription the viral DNA is flanked by LTRs, a repetitive sequence to
steer the integration of the provirus into the host genome. Furthermore, the 5′ LTR con-
tains the promotor for the entire gene expression of the virus, once the viral DNA has
been integrated. The 3′ LTR contains a polyadenylation signal as well as the gene for the
accessory protein Nef [50]. The gRNA of the virus is preceded by an untranslated region
(UTR) controlling various steps of the HIV life cycle including transcription, translation,
reverse transcription, export and virus packaging [51–54]. It forms different structures
according to the executed function, with an example shown in Figure 2.4, building the
following structural elements.
FIGURE 2.4: Structure model of the 5′ UTR in HIV-1: the TAR element, the
polyA stem loop, the PBS complex, and the Psi domain including SL1 (DIS),
SL2 (SD), the major packaging signal SL3, and SL4 with the gag start codon.
Graphic taken from [55].
Starting from 5′ to 3′, the target sequence for viral transactivation response (TAR) is lo-
cated in the beginning of the UTR, providing binding sites for the Tat protein and proteins
of the host cell important for transcription. The region forms a hairpin loop with a bulge
in the stem, which is important for its function.
It is followed by the polyadenylation site (5′ PolyA), which forms a stem loop and is in-
volved in genome packaging and dimerisation [56]. The primer binding site (PBS) binds
to a specific primer which is required for initiation of reverse transcription.
The packaging signal (Psi) domain is starting upstream the gag gene, partly overlapping
with it. It consists of four stem loops (SL) which are involved in genome packaging [51,
57, 58].
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The highly conserved SL1 contains the dimer initiation site (DIS), a palindromic loop,
which binds to a second gRNA strand to build a dimer by forming a kissing stem loop
during encapsidation [59]. The SL2 contains the splice donor (SD) site, involved in reg-
ulation of the splicing process to balance the level of synthesis for the viral proteins [60].
Great importance has been awarded to SL3, historically considered as the major packag-
ing signal (also referred to as Psi element) [61–63]. However, several studies revealed a
crucial role of SL1 for packaging in vitro [8, 12, 52, 64]. In Chapter 7, we will refer to the
major packaging domain in in cell experiments [12], exposing additional motifs within
the 5′ UTR involved in the viral packaging process. The SL4 stem loop starts right behind
the start codon for the Gag protein. Compared to the other SL elements, SL4 has a low
binding affinity to the NC domain during the packaging process. Hence, the authors of
[65] suggest that SL4 is involved in the genome recognition by stabilising the structure of
the Psi domain.
Another important structural domain is the Rev response element (RRE) within the env
gene. The segment is about 350 nucleotides long and binds to the Rev protein to be ex-
ported from the nucleus to the cytoplasm [66].
2.4 Replication Cycle
The replication cycle of HIV, illustrated in Figure 2.5, starts with the virion binding and
fusing with the surface of the targeted cell. The pre-integration complex, containing the
viral gRNA and proteins, is released into the cell. The capsule is degraded and the RNA
can be transcribed by the viral reverse transcriptase into viral DNA. After transporta-
tion of the DNA inside the nucleus, it is integrated into the host genome by the enzyme
integrase. The DNA of the host including the provirus is transcribed by the cell’s tran-
scription machinery. Multiple copies of the viral mRNA are formed. Some of them are
translated into viral proteins and some are packed into the new emerging virus particles
at the surface of the host cell, together with the translated proteins. After the release of the
immature virion, the viral protease inside of the virion cleaves the packed polyproteins
and a mature, infectious virus is assembled. In the following, the individual steps are
explained in more detail.
2.4.1 Cell Entry
The first phase of the life cycle of an HIV virion is the entry of the targeted cell, depicted
in detail in Figure 2.6. To bring virion and target cell into close proximity, quite unspecific
attachment mechanisms exist, which increases the efficiency of an infection [68]. Binding
to the surface of the cell is mediated by the viral envelope complex (Env) with gp120 bind-
ing to the CD4 receptor of the host cell, and subsequently to a transmembrane chemokine
co-receptor [68, 69].
The stable attachment of Env to CD4 and the co-receptor causes conformational changes
allowing the fusion peptide of p41 to enter the cell membrane. This mediates the fusion
of the viral membrane with the cell membrane, and, consequently, the entry of the viral
capsid into the host cell [68].
2.4.2 Reverse Transcription
The mechanisms happening between membrane fusion and establishment of the reverse
transcription complex (RTC) in the host cell are poorly understood [68, 70, 71]. When
exactly the RTC is constructed, and hence the reverse transcription starts, still remains
unclear. It is assumed that the gRNAs together with viral proteins are released into the
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FIGURE 2.5: Replication cycle of HIV. Graphic taken from [67].
host cell after the uncoating procedure, where the viral capsid is disassembled [72]. Sub-
sequently the RTC is constructed comprising structural proteins MA, NC, the enzymes
RT and IN, and the accessory protein Vpr, starting with the reverse transcription process
[70, 71]. However, some research teams report an onset of reverse transcription within the
capsid directly after the viral entry or even within the unfused virion [72].
The heterodimer reverse transcriptase removes the nucleocapsid proteins from the RNA
and produces complementary DNA copies (cDNA). It uses both RNAs as templates and
switches frequently between the strands to be transcribed during the copy process. If
the initial virion contained two distinct gRNAs new recombinants emerge during this
process. Furthermore, because the reverse transcription process is highly error prone
(mutation rate per base around 10−5), the initial HIV genome gets modified by multi-
ple mutations. This causes a vast variety of heterogeneous HIV species ("quasispecies"),
consequently allowing the virus to evade the human immune response and attain resis-
tance against antiviral drugs [71].
The reverse transcriptase also occupies ribonuclease and DNA polymerase activity: the
RT degrades the transcribed RNA and produces a complementary (positive sense) copy
of the cDNA such that a double stranded DNA molecule can be formed [71].
2.4.3 Nuclear Import and Integration
Shortly after the final steps of reverse transcription the RTC forms the pre-integration
complex (PIC). The double stranded viral DNA is imported into the nucleus, with MA and
Vpr carrying nuclear localisation signals (NLS). It is assumed that the PIC interacts with
the cellular machinery that executes the host’s own nuclear import of karyopherin [73].
Also the enzyme integrase is part of the PIC and plays an important (but not very clear)
role for the import [71, 73, 74]. It is known that MA interacts with the core domain of the
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FIGURE 2.6: Fusion of HIV with the target cell. After attaching to the host
cell, the viral Env protein binds to the CD4 receptor, and the co-receptor of
the cell. Conformation changes allow the fusion glycoprotein gp41 to pen-
etrate the cell membrane, which mediates the fusion of the viral membrane
and the cell membrane. Graphic taken from [68].
integrase [74]. Moreover, [75] showed that the viral DNA itself possesses a strand overlap,
obtained during reverse transcription, that mediates the import into the nucleus.
After the transfer, the double stranded viral DNA is inserted into the host cell genome by
integrase in several steps: clipping nucleotides from the 3′ end of both strands, staggered
cleavage of the target host DNA and integrating the viral strands. Cellular repair enzymes
mend arisen gaps at the attachment sites [71].
2.4.4 Replication and Nuclear Export
The integrated viral DNA, referred to as "provirus", is transcribed like host own genes
with the necessary support of cellular transcription factors, but encoding the full informa-
tion of structural, regulatory, and accessory proteins used to direct virus replication [71].
One of the most important transcription factor, nuclear factor kappa B, promotes the ex-
pression of genes which largely participate in the host immune response. As a conse-
quence, those cells that are actively fighting an infection are most likely to be infected and
subsequently killed by HIV [76].
A large number of viral mRNAs are transcribed (more than 30). They are further pro-
cessed in three ways [71]:
• The mRNA is spliced multiple times into small fragments (1.7 to 2.0 kb) to be trans-
lated into the proteins Rev, Tat (encouraging new virus production), and Nev.
• Partially spliced mRNA (∼5 kb) is translated into the proteins Env, Vif, Vpu, and
Vpr.
• The mRNA remains unspliced and serves as mRNA for Gag and GagPol polypro-
tein precursors, and is packed into new virions as full-length gRNA.
The small, fully spliced viral mRNAs can be transported to the cytoplasm for translation
with the export mechanism of the cell for its own mRNAs. After the viral Rev protein
is translated in the cytoplasm, it enters the nucleus, binds to the RRE domain present in
unspliced and partially spliced RNA, and mediates the nuclear export of these [71].
Gag is expressed as a 55 kDa polyprotein precursor (Pr55Gag), and is the key player for
the viral assembly step. A frame shift during translation of Gag enables the production of
the 160 kDa GagPol polyprotein precursor, which contains the enzymes PR, RT, and IN.
GagPol yields a rate of ∼5% of the Gag production [71, 77].
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2.4.5 Assembly and Maturation
After protein synthesis and nuclear export, the assembly process, depicted in Figure 2.7,
is initiated at the plasma membrane of the cell.
FIGURE 2.7: Assembly of virions. Graphic taken from [77].
Pr55Gag is the main driver of the viral assembly. After translation in the cytosol it interacts
with the gRNA-dimers. The untranslated gRNA molecules are dimerised after transfer to
the cytosol through intermolecular base-pairing [78], which is crucial for packaging into
assembled virions. The main determinant in Gag for packaging of the gRNA-dimer is the
NC domain, which binds to the packaging signal in the 5′ UTR of the gRNA [77, 79, 80].
However, studies showed that the Gag-RNA interaction changes through assembly and
maturation processes [77, 81]. They revealed that after arrival to the cell membrane and
during virus assembly the molecules are linked at several sites throughout the genome.
The NC-RNA-interaction plays also a role in Gag multimerisation, however, the main
driver for the Gag assembly is the CA domain in Gag.
The transport of Gag to the plasma membrane is mediated by the MA element. Here, Gag
targets lipid raft microdomains of the membrane to start the assembly of the virus [82–
84]. For building the immature virus particle, Gag molecules are connected and packed
with the MA domain building the inner matrix of the viral membrane and the C terminus
towards the virus centre [71, 77]. Also the GagPol polyprotein precurser is packed into
the nascent virus via Gag-Gag interactions [71].
The viral Env glycoprotein is synthesised in the rough endoplasmatic reticulum (ER) of
the cell from the translated Env precursor protein gp160 and transferred through the
Golgi. From here it is transported within vesicles to the cell membrane [71]. The specific
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mechanism how Env is incorporated into the nascent virus is not completely resolved [77].
One of the theories promotes a central role for the MA domain of Gag interacting directly
with the gp41 part of Env. This assumption is supported by several research results [85–
88]. Thus, the viral assembly engages Gag as the central determinant building Gag-RNA,
Gag-Gag, Gag-lipid and Gag-Env interactions.
After the immature Gag lattice is assembled at the membrane, the release of the virus par-
ticle is achieved through Gag taking over the cellular ESCRT machinery, which is respon-
sible for membrane budding and fission processes [77]. The so called late- or "L"-domains,
located in the p6 N-terminus of Gag, trigger the membrane scission [71, 77].
The maturation process starts shortly after budding off. It is a highly ordered multistep
process involving a cascade of conformational switches and subunit rearrangements [44,
77]. The viral enzyme protease in the immature virion cleaves the polyprotein precursors
Gag and GagPol into the actual mature proteins, including the structural elements of the
virus (MA, CA, NC), and the viral enzymes (PR, RT, IN) respectively. The cleavage of
the polyprotein precursors is accompanied by morphologic changes of the virion. The
immature virus contains the Gag molecules in a radial composition, whereas the cleaved
CA proteins form a conical capsid around a complex built by the RNA, NC, and RT. The
matrix proteins remain at the inner leaflet of the viral membrane [44, 77]. The mature
virus is now capable of infecting new host cells.
2.5 Treatment
The life cycle of HIV involves many crucial steps, each of them being a potential target for
antiviral drug development. One of the first targets was the reverse transcription process.
In 1987, the first antiviral therapy (ART), Zidovudine (AZT), was approved for clinical
treatment of HIV-1 patients [89], only four years after the discovery of HIV being the
cause for AIDS.
AZT is a nucleoside analogue which inhibits reverse transcription when incorporated into
the nascent DNA strand. Shortly after, several other RT targeting drugs were developed.
However, due to the high mutation rate of RT, resistance mutations could emerge rapidly
after beginning of the treatment. Especially the fact that the therapy initially started with
only one medicine reinforced the development of resistant virus strains [71].
Current HIV regimen include three different drugs of at least two drug classes [5]. The
four major classes acting on essential steps of the HIV life cycle are briefly listed below
with respective drug names.
• RT inhibitors: NRTIs (nucleoside reverse transcriptase inhibitors) are nucleoside
analogues averting the reverse transcription process by competing with nucleosides
and stopping reverse transcription
→zidovudine, abacavir, lamivudine, emtricitabine, tenofovir
NNRTIs (non-nucleoside reverse transcriptase inhibitors) bind to an allosteric site
of the enzyme to inhibit reverse transcription
→efavirenz, nevirapine, etravirine, rilpivirine
• PIs (protease inhibitors): blocking protease to prevent the cleavage of Gag and Gag-
Pol precursor proteins resulting in uninfective immature virus particles
→lopinavir, indinavir, nelfinavir, amprenavir, ritonavir, darunavir, atazanavir
• Entry inhibitors: including fusion inhibitors which block HIV Env from merging
with the host CD4 cell membrane to prevent the fusion of viral and cell membrane,
and inhibitors blocking receptors and co-receptors on the cell surface
→maraviroc, enfuvirtide
2.5. Treatment 13
• INSTIs (integrase nuclear strand transfer inhibitors): interfering with the enzyme
integrase to prevent integration of the viral DNA into the host DNA
→raltegravir, elvitegravir, dolutegravir
The combination therapy is also known as HAART (highly active antiretroviral treat-
ment). Potent treatment results are achieved by including a "backbone" of two NRTIs
in combination with a INSTI, an NNRTI, or a PI [90]. The treatment with HAART al-
lows to manage the chronic disease by keeping the number of virions in the body (viral
load) low, maintaining a functional immune system and preventing the development of
serious, often lethal opportunistic infections [91, 92]. Additionally, the low viral load de-
creases the probability of transmission to an uninfected person [92]. Although drug side
effects occur, HIV patients can live an almost normal life with a close to ordinary life ex-
pectancy [92]. Yet, due to its high mutation– and replication rate, HIV manages to escape
drug treatment and develop multiresistance resulting in complete treatment failure.
Furthermore, common therapy regimen do not work optimally for HIV-2. HIV-2 is intrin-
sically resistant to NNRTIs. It still remains a critical challenge to clearly define the best
strategy to treat HIV-2 [93]. Thus, thorough investigation of viral dynamics and evolution






In this chapter, we give a few definitions of evolutionary genetics:
First, we introduce the term fitness and look at fitness landscapes. These landscapes com-
prise evolutionary paths, which are useful to infer evolutionary constraints. In the sub-
sequent section we will explore biological constraints in more detail. These constraints
include among others genetic interactions, so called epistasis, which we consider in the
last section.
3.1 Fitness
In population genetics, the fitness of a certain genotype (the genetic variant) or phenotype
(observable characteristics) of an organism denotes a quantitative measure of the ability
to reproduce in a given environment [94, 95]. The fitness may be broken down into vari-
ous components (traits), but essentially it denotes surviving, and propagating its genetic
material in the gene pool (the set of all genetic information in a population). The fitness of
an individual is quantified by its average contribution in the gene pool of the successive
generation. Hence, it depends on the background population. Additionally, the fitness of
one phenotype can be different in distinct selective environments, i.e. the fitness is also
influenced by external conditions.
In the perspective of evolutionary biology, fitness is assigned to the genotype instead of an
individual organism and is measured by its reproductive success or "replication rate" [96].
This can be either absolute fitness, or more common, the relative fitness in relation to a
reference sequence (e.g. wild type, or the genotype with the highest fitness). Here, fitness
is considered as the phenotype of the genotype.
In every new generation of the organisms, the genotypes do not retain the initial sequence,
but undergo genetic changes, including mutation, and recombination of distinct geno-
types. Hence, the fitness of an organism can be broken down into fitness measures of
genetic fragments (e.g. genes) with respect to the average genetic background.
After several generations of replication, the fittest genotype of the regarded trait is very
likely most prevalent in the gene pool, resembling the natural selection process, i.e. the
Darwinian evolution theory [96].
Fitness landscapes are used to visualise the fitness of different genotypes [96, 97]. An ex-
ample for a protein sequence with two residues is shown in Figure 3.1. Here, the plain of
the surface, x- and y-axis, represent different genetic variants of two distinct genetic loci,
and the vertical z-axis shows the respective fitness of the genotype with the combination
of the two variants. Genotypes that are similar are close on the axis. The more differences
in the genome, the more they are apart in the landscape. This enables the identification
of local fitness peaks, i.e. genetic variants with comparatively high fitness, and fitness
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FIGURE 3.1: Fitness landscape showing the replicative fitness of the se-
quence space comprising two loci (here protein residues) for all combina-
tions of variants (20 amino acids). Figure taken from [98].
valleys, comprising genotypes with low fitness. The landscape can be evaluated by its
density of peaks (and valleys), giving the ruggedness, or contrarily, the smoothness. To-
gether with other properties of the fitness landscape, the ruggedness contains reference to
the speciation process in the evolution of the gene pool.
The fitness landscape represents a network of all possible trajectories between all geno-
types, moving along the path of genotypes that differ only at a single position [99, 100],
depicted in Figure 3.2. As mentioned above, the evolutionary path of a population is
FIGURE 3.2: Fitness landscape for a sequence of length 2 with two possible
symbols per positions, A and B. The trajectory of the evolutionary path
moves from low fitness to high fitness. The sequences are connected if they
differ at only one position.
usually restricted to paths of increasing fitness, especially under conditions with strong
selection and low mutation [101]. In the example in Figure 3.2, we have a sequence of
length 2. Each position can comprise one of two symbols, A and B. The red arrows depict
the paths towards the variant "BB", which is a local/global maximum. Only the sequence
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variant "AB" is less fit than "AA". The pathway starting from "AB" might propagate to-
wards the maximum "BB", or to "AA" (blue arrow), and then subsequently towards "BB".
Since, fitness is depending on the background and the environment, any change of the
conditions can induce a shift of the fitness landscape and hence the evolutionary paths.
Fitness valleys constitute constraints for the evolutionary development. If the trajectory
from a genotype with medium fitness to a peak contains a valley, it is less likely that the
gene pool evolves towards the peak. In our example, that would be the case, if both "AB"
and "BA" have lower fitness than "AA" and "BB".
In the next section, we are going to elaborate on evolutionary constraints in more detail.
3.2 Constraints
Constraints in a biological point of view are factors which limit evolutionary change.
These factors may be intrinsic (genetic variants) or extrinsic (selective pressure among the
species) causes to prevent a phenotype to adapt and reproduce. They restrict the number
of evolutionary paths, or phenotypes that may emerge in the future [102].
As discussed in several publications [103, 104], the term evolutionary constraint is very
manifold and inconsistently defined.
In essence, evolutionary constraints can be interpreted as specific factors, which pre-
vent the transition of an established trait to a more advantageous state or selective op-
timum [104, 105].
Various types of constraints were discussed in literature, which describe either the re-
garded trait, the level of variation or the cause of the constraint [103]. Several reviews
discuss and try to disentangle the wide range of terminologies and definitions [104, 105].
Evolutionary constraints can be divided into different groups of abstractions, but they are
highly connected.
In the following we briefly summarise different categories.
On the lowest abstraction level are genetic constraints. They are determined by the
amount or patterns of genetic variation which may limit the adaption of a trait [104].
This includes epistatic interactions (cf. Section 3.3) and pleiotropy, i.e. the influence of
one single gene on multiple phenotypic traits.
Developmental constraints are caused by a variety of factors including for example struc-
tural restrictions, biological scaling in relation to size (allometry), and similarities in early
stages of embryonal development of vertebrates [105]. Constraints due to developmental
force are closely connected to genetic constraints, as they largely determine the required
genetic interactions [104]. On the other side, they influence phenotypic development by
conditioning, which heritable phenotype variation is exposed to environmental factors
and hence, natural selection [106].
Selective and functional constraints, also referred to as adaptive trade-offs [105], are
given, when the selection of one trait or function effects, or even prevents, another trait
to evolve towards adaption [104]. Thus, the selective constraint is in regard to a specific
trait, which is limited by selection of correlated functions. This can be either by preference
of another trait, or selective pressure of different factors acting on this particular trait. The
selection can either be external or internal [107]: External selection corresponds to the
classical Darwinian definitions of an organism interacting with and adapting to its envi-
ronment. Internal selection is referring to the interaction of internal components enabling
the response to external factors. Again, these constraints are in close coherence with ge-
netic interactions constraining evolution.
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Phylogenetic and historical constraints denote the influence of the preceding develop-
ments in the past, and how ancestry stirs evolution in particular directions by constrain-
ing the possible variation. The illustrative example in [104] makes the concept more clear.
Regarding different animals swimming in the sea: they are all well adapted to move in
water. Yet, they developed different methods to swim depending on the ancestral origin.
The penguin uses the inherited wings for swimming and a whale bred a horizontal fluke
out of hind-legs. These constraints are highly affected by developmental constraints.
In the following section we explore details of genetic constraints, i.e. epistasis.
3.3 Epistasis
The term epistasis, originally describing the interaction of gene loci, covers a variety of
different definitions and interpretations among different scientific fields. In essence, epis-
tasis gives the deviation from an expected outcome of independent effects.
The expression "epistatic" was initially used by Bateson [108] in 1909 to explain models of
natural selection beyond dominant and recessive alleles on individual loci. Back then, it
described the ability of a pair of gene alleles at one locus ("allelomorphic pair") to mask
the phenotypic effect of another locus, meaning one of the loci is dominating the other lo-
cus. Over time, with the progression of genetic research, this definition has been extended
to more complex gene interaction models [109, 110]:
Epistasis is given
• whenever an effect is masked by the absence or presence of an attribute,
• when an effect of one allele is modified by one allele (or more) of another locus,
• or, if at least two loci interact such that a new phenotype emerges.
Also quantitative genetics started to adopt the idea of epistasis, though these definitions
depart even more from the original meaning. Fisher et al. used "epistacy" to describe gene
interactions generating statistical deviation from additive effects on quantitative pheno-
types [111].
In general, the quantitative interaction analysis defines two components. A quantitative
phenotypic measure and a neutrality function, representing the phenotype without inter-
action. The epistasis is given by the deviation of the expected neutral phenotype [112]. In
molecular– and evolutionary biology the techniques to quantify effects of genes and gene
interactions on measurable attributes advanced. These measurable attributes include for
example pigmentation, catalysis, or growth rate.
The latter is one type of fitness epistasis, which describes interaction of distinct genetic
sites affecting the fitness of the genotype.
Here, we are considering the measure as the decrease/increase of the mutant population
relative to wild type after one generation. In the following, we will introduce different
neutrality functions and types of interactions that may occur.
3.3.1 Neutrality Functions
To describe the variety of neutrality functions, we consider a haploid organism (one set of
genes), with two genotype variants for each locus, wild type and mutant, indicated with
a small and capital letter respectively. The quantitative phenotype is a fitness function f ,
i.e. f (ab) gives the fitness of the wild type and f (AB) denotes the neutral fitness of the
double mutant for loci a and b, without interaction.
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3.3.2 Multiplicative Model
The definition of the multiplicative neutrality function is given by
f (AB) · f (ab) = f (Ab) · f (aB). (3.1)
If the fitness measure is given in relation to the wild type, we have f (ab) = 1 and thus
f (AB) = f (Ab) · f (aB). (3.2)
The epistasis is given by
Eab =
f (AB) f (ab)
f (Ab) f (aB)
. (3.3)
3.3.3 Additive Model
If two co-occurring mutations have the same effect as the sum of the individual effects,
they are purely additive without any interaction. The interaction can be formulated as
f (AB) + f (ab) = f (Ab) + f (aB) (3.4)
The epistatic effect of a double mutant is attained with
Eab = f (AB) + f (ab)− f (Ab)− f (aB). (3.5)
The multiplicative model can also be expressed as additive model by transforming the
fitness into the log scale:
log Eab = log
(
f (AB) f (ab)
f (Ab) f (aB)
)
= log f (AB) + log f (ab)− log f (Ab)− log f (aB). (3.6)
3.3.4 Measures of Epistasis
The various types of epistatic interactions are illustrated in Figure 3.3 and are explained
in the following.
Magnitude Epistasis
If the magnitude of the effect, yielded by the double mutant, deviates from the purely
additive effect of the two individual mutations, an epistatic interaction is given. Positive
epistasis is given, if the fitness is higher than expected, i.e. two beneficial mutations have
amplification in fitness when occurring in combination, and two deleterous mutations
have less fitness loss than the sum of the individual mutations. In conversion, if the phe-
notype is less fit than expected, negative epistasis is given.
Synergistic epistasis describes the enhancement of the either positive or negative ad-
ditive fitness magnitude. On the contrary, antagonistic epistasis is a reduction of the
magnitude for a pair of beneficial, or deleterious mutations, i.e. less severe effects than
expected. The interpretation of the actual effect on fitness depends on the context of the
two single mutations [112, 114]. An example for antagonistic interactions is a mutation at
one particular site, which is highly deleterious and masks the effect of additional muta-
tions.
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FIGURE 3.3: Different types of epistasis between two point mutations. Fig-
ure taken from [113].
Sign Epistasis
The concept of sign epistasis states that the effect of a mutation depends on the genetic
background of the population, which means the mutation can be beneficial for some of
the genotypes and deleterous for others [115]. Thus, the sign of the effect of a mutation is
under epistatic control. An example would be a mutation that is deleterious if it appears
individually, but enhances the effect of a beneficial mutation.
A more extreme case is the reciprocal sign epistasis, where the sign of the effect changes
for both mutations when ocurring together, i.e. both mutations have a negative effect on
its own, but are beneficial (positive) in co-occurrence [99].
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Chapter 4
Methods to infer Evolutionary
Constraints
This chapter gives an overview of current techniques for the inference of evolutionary
constraints using closely related biological sequences. These sequences are aligned in a
multiple sequence alignment (MSA) of a biologically relevant length, with each column
representing the distribution of symbols at one position of the sequence. Hence, an MSA
contains information about the sequence conservation and allows to assess correlations
between two residues of the sequence, which give some indication of evolutionary con-
straints. Co-evolution in sequences is an essential component to understand evolutionary
relationships and comprehend functional developments.
A great variety of methodologies have been established in the last decades considering
MSAs with the goal to predict functional and structural constraints within polymeric
molecules [116].
One of the first approaches to detect covarying sequence pairs in a biological context
was introduced by Korber et al. in 1993 [117], applying techniques based on information
theory. Finding interdependent amino acid frequencies by mutual information of two se-
quence residues facilitated the identification of co-evolving mutations. These may give
implications for structural or functional relationships between those residues. Improve-
ments of the basic method accounted for and corrected for false positives caused by sam-
pling biases and phylogenetic effects [118–120]. Another approach, sometimes known as
so called McLachlan-based substitution correlation (McBASC), uses correlation measures
to extract substitution patterns of two positions of an MSA[121–123]. This information is
used to predict residues in close proximity within three-dimensional protein structures.
Other methods use phylogenetic approaches detecting patterns of simultaneous amino
acid substitutions [124, 125].
As we will explain in the following sections, an important obstacle is the distinction of
direct couplings from indirect relations, which occur when more complex substitution
patterns involving more than two positions exist. Initially proposed by Lapedes et al.
[126], the idea was seized in the recently developed direct couping analysis (DCA) [9,
127, 128], as well as the method of protein sparse inverse covariance estimation (PSI-
COV) [129]. Both methods construct a global statistical model of the MSA to infer direct
couplings. An alternative approach predicts pairwise protein-protein interactions with an
parameter-free Bayesian network [130].
In this chapter, we present dependency measures based on information theory. First, we
introduce the input data, an MSA of biological sequences. After briefly discussing mu-
tual information, the main focus is put on direct coupling analysis. For the latter, the
derivation of the maximum entropy model is described and the resulting Potts model is
explained broadly, including its origin in statistical physics. Different approaches for the
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inference of the model parameters are presented, and various scoring schemes for the
evaluation are discussed.
4.1 Representation of Biological Sequences and MSA
Each biological sequence σ = {σ1, . . . , σL} is composed of L symbols from the alphabet A
containing a set of q different symbols. A protein sequence would consist of 20 different
amino acids (or 21 symbols including a gap) and a DNA or RNA sequence consists of 4
nucleotides (or 5 characters including a gap).
The MSA M (an example shown in Figure 4.1) contains the aligned sequences, result-
ing in a matrix of residues with M sequences as rows and L columns for each sequence
position:
M = {Mai }, with i = 1, . . . , L and a = 1, . . . , M. (4.1)
FIGURE 4.1: MSA of RNA sequences with M = 10 rows and L = 34
columns.
For simplicity of the notation the q symbols are translated into consecutive numbers
1, . . . , q.
The empirical residue frequencies for single positions and pairwise positions contained














δ(A,Mai ) · δ(B,Maj ) (4.3)
with 1 ≤ i, j ≤ L and 1 ≤ A, B ≤ q, and the Kronecker-symbol δ being 1 if the symbols
are equal and 0 otherwise.
In the MSA in Figure 4.1, for example, the marginal frequency in the second column for
nucleotide G is f2(G) = 0.4 and in the third column for nucleotide A is f3(A) = 0.4. The
pairwise frequency is f2,3(G, A) = 0.1.
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4.2 Mutual Information
In information theory, mutual information (MI) is a local correlation measure of how de-
pendent two random variables are. It quantifies the amount of information one random
variable reveals about another variable, hence how much information they share. MI is
closely linked to the variability or uncertainty of random variables, the so called entropy,
defined by Claude Shannon [131]:
MI(X, Y) ≡ H(X)− H(X|Y)
≡ H(Y)− H(Y|X)
≡ H(X, Y)− H(X|Y)− H(Y|X)
≡ H(X) + H(Y)− H(X, Y) (4.4)
with H(X) and H(Y) the marginal entropies of the random variables X and Y respectively,
H(X|Y) and H(Y|X) giving the conditional uncertainties of one variable with knowledge
of the other one and H(X, Y) is the joint entropy of X and Y. The relation is depicted in the
Venn diagram in Figure 4.2. The mutual information measures how much the knowledge
FIGURE 4.2: Venn diagram depicting the set-theoretical relationship of mu-
tual information (MI(X, Y), purple intersection area) and entropy H of
correlated random variables X and Y. The red and blue circles show the
marginal entropies H(X) and H(Y) respectively, substracting the intersect-
ing purple MI result in the conditional entropies H(X|Y) and H(Y|X). The
joint entropy H(X, Y) is indicated by the purple dashed line.
about one variable reduces the uncertainty about the other one. If two variables are abso-
lutely independent, the knowledge about one of the variables gives no information about
the other one, thus the MI is zero. With maximal MI, the uncertainty about the random
variable vanishes, the two variables are deterministically connected and the information
conveyed for one of them includes all information about the other variable.
Given the discrete random variables X and Y, the mutual information is denoted by










with the joint probability distribution function P(x, y) of X and Y and the respective
marginals P(x) and P(y) for X and Y. The MI is zero if and only if the two variables
are independent: MI(X, Y) = 0←→ P(x, y) = P(x) · P(y). Moreover, MI is nonnegative,
i.e. MI(X, Y) ≥ 0, and symmetric, i.e. MI(X, Y) = MI(Y, X).
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fi(A) · f j(B)
)
, (4.6)
where fi(A) and f j(B) denote the frequencies of symbols A at position i and B at position
j, fij(A, B) gives the observed co-occurrence of symbols A and B at positions i and j within
the MSA.
4.3 Direct Coupling Analysis
Direct coupling analysis (DCA) is the generic name for a collection of several methods
analysing sequence data, like proteins or RNA. The main idea is to use statistical mod-
elling to extract the direct relation of two positions within an MSA of homologous se-
quences without confounding effects from other positions.
Common methods to derive the correlation in an MSA, for example mutual information
(cf. Section 4.2), use only local measures, i.e. only the frequencies of two particular
residues are taken into account. Pairs are considered in isolation and indirect associa-
tions might be inferred, simplified shown in Figure 4.3. Transitive pair correlations can
confound the true result.
FIGURE 4.3: Correlation analysis. Pearson’s correlation yields interactions
between all three compounds A, B, and C. The partial correlation reveals
the true correlations between A and C. Figure taken from [132], based
on [133].
In DCA, co-evolving nucleotides are identified by using a global statistical model: P de-
scribes the probability of occurrence of the nucleotide sequence as a joint probability dis-
tribution in the sequence space. The aim is to derive the simplest possible probability
model explaining the observed data, which will be explained in detail in the next section.
4.3.1 Derivation of the Maximum Entropy Model
DCA aims at modelling the sequence variability in the input MSA via a generalised Potts
model, which is derived by using the principle of entropy maximization [134]: informa-
tion and information entropy are linked. The more information in the system, the lower
its entropy and vice versa.
The principle of maximum entropy states that, subject to precisely stated prior data the
probability distribution which best represents the current state of knowledge is the one
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with the largest entropy.
Thus, we search for a probability distribution P for sequences σ:




2. being compatible with the measured single and pair frequencies
Pi(A) = fi(A) (4.8)
Pij(A, B) = fij(A, B) (4.9)
3. maximising the information entropy
maximise H = −∑
σ
P(σ) ln P(σ) (4.10)
Lagrange multipliers are used to find the stationary point of a function subject to equality
constraints and thus the Lagrangian for the function is given by























Pij(σi, σj)− fij(σi, σj)
)
. (4.11)
The stationary point is found by setting the functional derivative of L with respect to the





























































The Lagrangian multiplier α is not a free parameter because it can be fully determined for
given β and γ by the normalisation constraint Z ≡ exp(1− α). Because of the symmetry
of the Lagrangian multipliers γij(a, b) = γji(b, a) and δσi ,a · δσi ,b = 1 ⇐⇒ a = b, the free
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parameters can be reduced to
hi(a) := βi(a) + γii(a, a) and (4.15)
gij(a, b) := 2γij(a, b) for i < j (4.16)














for a system of q = 2 states known as the Ising model and for the multivariate case with
q > 2 known as the Potts model.
The Potts Model
In statistical physics, the Potts model is a generalisation of the Ising model: it describes
a system of L interacting variables or spins with q different states on a lattice. The La-
grangian multipliers can be interpreted as local magnetic fields h acting on individual
spins within the system and the coupling strength g encoding pairwise interactions. The















specifiying the energy of a spin configuration (or sequence) σ ≡ {σ1, . . . , σL}. The temper-
ature is incorporated into the couplings and fields such that kT = 1. Z is the normalising













Collectively, magnetic fields and couplings are the parameters of the Potts problem. If the
couplings and fields are given, the forward problem is to compute the single site mag-
netisations and pair correlations under the Boltzmann distribution.
The inverse problem is seen from the reverse direction: with existing statistical observ-
ables the unknown fields and couplings are derived.
Gauge Fixing
The parameters h and g of the model have to be fitted.
In order to get a unique solution for the model, the number of independent constraints
has to match the number of free parameters to estimate. The problem here is, that depen-
dencies of constraints due to
1 = ∑
A∈A
Pi(A) and Pi(A) = ∑
B∈A
Pij(A, B) ∀ i, j = 1, . . . , L
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lead to a number of (L2)q
2 + Lq free parameter to estimate versus (L2)(q − 1)2 + L(q − 1)
independent constraints.
To ensure uniqueness of the estimated parameters and the probability distribution, the
number of free parameters has to be reduced (so called gauge fixing).
There are different solutions of creating dependencies of parameters, for example
• setting parameters corresponding to the last symbol in the alphabet q to zero:
gij(q, ∗) = gij(∗, q) = hi(q) = 0
• zero-sum gauge: ∑qa=1 gij(A, B) = ∑
q
a=1 gij(B, A) = ∑
q
a=1 hi(A) = 0
The different variants for gauge fixing are not equally efficient, depending on the scor-
ing scheme. For example, the zero-sum gauge is suitable for non-gauge invariant scoring
functions like the (APC) Frobenius norm, because it minimises the sum of squares of the
pairwise parameters.
Some scoring schemes do not require any gauge fixing, like the L1 and L2 regulariser in
maximum likelihood-based estimation. Here, the regulariser selects for a unique repre-
sentation among all parametrisations of the optimal distribution.
4.3.2 Parameter Inference
Parameters h and g have to be determined obeying the constraints in Equations (4.8) and
(4.9). The main problem is the determination of Z, which requires the computation of the
Hamiltonians of the whole sequence space, consisting of qL sequences, hence taking ex-
ponential time. The calculation of exact results is thus infeasible, especially for large data
sets.
Different strategies have been proposed to approximate the model parameters, nicely re-
viewed in [10]. In the following we will present a variety of approaches to ascertain the
parameters, with emphasis on the mean field approximation and its modifications.
Maxmum Likelihood
The inverse Potts problem involves the reconstruction of unknown parameters via statis-
tical inference. Basis for many methods to infer these parameters is the maximum likeli-
hood framework.
We suppose that the variables X = (X1, . . . , Xn) are drawn i.i.d. from the density function







the probability of observing the data x1, . . . , xn with given parameter θ. The same func-
tion viewed as a function of θ at fixed data x refers to the likelihood L(θ; x) of the param-
eters θ taking certain values given the observed data x [10].
The maximum likelihood estimator (MLE) finds the values for the model parameter θML
that maximise the likelihood function L(θ; x), hence the parameter set that make the data
most probable:
θML = arg max
θ
L(θ; x1, . . . , xn). (4.22)
With finite sampling, it is improbable to determine θ exactly. However, the MLE pos-
sesses a number of attractive limiting properties with infinitely increasing sample size,
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which allow to converge to the parameters θ [135]. Consistency is one of these properties.
It means that if a sufficiently large number of data were generated by the common density
function P(x; θ), the sequence of estimators θML converges in probability to the original
parameters θ with arbitrary precision.
To avoid the computation with very small numbers, because the likelihood scales expo-
nentially with the number of samples, it is more convenient to maximise the logarithm
of the likelihood. This leads to the same parameter estimates since the logarithm is a
strictly monotonic function. Applied to the inverse Potts problem, where M configura-
tions S = {s11, . . . , s1L, . . . , sM1 , . . . , sML } are sampled from the Boltzmann distribution, cf.




ln L(h, e; S)










gij(A, B) · fij(A, B). (4.23)
The log-likelihood depends on the parameters of the Potts model, as well as the mag-
netisations and the correlations between pairs of spins. The sample averages provide
sufficient statistics to determine the model parameters. Hence, the observed pairwise fre-
quencies fij and single site frequencies fi can be used to determine the parameters h and
g.
Interpreting the log-likelihood in the context of thermodynamics, it can bee seen as the
entropy of the Potts model [10]. The first term of the equation is known as the free energy
and the latter two terms are the sample average of the energy. Approaches to approximate
the model parameters utilise this property, thus we consider this relation in more detail.
Thermodynamic Potentials for the Inverse Potts Problem
In statistical physics, the introduction of thermodynamic potentials helps to solve certain
problems. Thermodynamics explain the behaviour of physical systems by giving the re-
lation between the temperature, entropy, internal energy (the total energy of the system),
and pressure. The thermodynamic state of such a system is described by potentials in-
cluding the Gibbs and Helmholtz free energies. They describe quantitative measures of
the stored energy in a system, depending on different variables and constraints (i.e. fixed
variables), respectively.
Applying a Legendre transformation (see Infobox 4.1) allows to convert between these
potentials and to change the independent variables, hence to perform calculations with
the more convenient potential. For the Ising and the Potts model, the MLE of the system
parameters corresponds to such a transformation of thermodynamic potentials [10].
Regarding the forward problem, i.e. magnetic fields h and couplings g are given, the
derivatives of the Helmholtz free energy
F (h, e) = − ln Z(h, e) (4.24)
allow to determine observables, i.e. the first and second moments of the distribution. In
the context of thermodynamics, we will refer to magnetisations m and pair correlations
χ. Thus, we can note here that all necessary information on the marginals can by derived
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= −χij(A, B) + mi(A)mj(B) ≡ −Cij(A, B) (4.26)
The derivative with respect to g can also be generated by a partial differentiation with
respect to h. It implies the connected correlations (covariance) C, with Cij ≡ χij −mimj.
Infobox 4.1: Legendre transformation




1. y = ∂ f∂x
2. f˜ (y) = x(y) · y− f (x(y))
Properties:
• all information for (re–)transformation are given in the func-
tion (no external information necessary)
• transformation is own inverse transformation
T2 = 1, T = T−1
• simple differentials
d f = ∂ f∂x dx = y dx
d f˜ = d(xy− f ) = dx y + x dy− d f = x dy
• allows to convert problem into a representation with more con-
trollable variables, which is more convenient to handle
(particularly useful in thermodynamics)
Example:
Equation:
f (x) = (x− a)2






















˜˜f (z) = y(z) · z− f˜ (y(z)) = 2(z− a) · z−
(




= (z− a)2 =
z=x
(x− a)2 = f (x)
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The inverse problem, i.e. pair correlations χ and magnetisations m are given, can be
solved by considering the Legendre transform of the Helmholtz free energy with respect











gij(A, B)χij(A, B)−F (h, e). (4.27)
It is also recognised as the entropy function and corresponds to the negative maximum
likelihood of the model parameters in Eq. (4.23).




gij(A, B) = − ∂S(m,χ)
∂χij(A, B)
. (4.29)
The inverse transformation of Equation (4.27) is given by










gij(A, B)χij(A, B)− S(m,χ). (4.30)
The thermodynamics of the inverse problem can be reduced to a single Legendre trans-
form, because as mentioned above, the derivatives of the Helmholtz potential w.r.t g can
be attained with the partial differentiation w.r.t. h (cf. Eq. (4.26)). The reduced Legendre








hi(A)mi(A)−F (h, e), (4.31)
which depends now on the single site marginal m and couplings g. Note, that the Potts
variables A only run until q − 1, as the qth variable is set to zero for gauge fixing (Sec-
tion 4.3.1).
The local field can be found by the first derivative of the Gibbs potential
hi(A) =− ∂G(m, e)
∂mi(A)
. (4.32)
Using the following inverse function theorem[
∂(h1, . . . , hN)





∂(m1, . . . , mN)




and taking the determination of the covariance matrix in Equation (4.26) into account






= (C−1ij )(A, B). (4.34)
This result turns out to be central to many methods for the inverse Ising and Potts prob-
lem [10]. As soon as the Gibbs potential (Eq. (4.31)) can be evaluated, the couplings
are easily to derive. Plugging these coupling estimates and single site marginals into
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Eq. (4.32) allows the determination of the magnetic fields h and thus the complete recon-
struction of the parameters for the model.
Mean Field Approximation
Mean field (MF) theory, also known as self-consistent field theory, has its origin in statis-
tical physics where problems with high dimensional probability distributions need to be
approximated. Certain dependencies between random variables are neglected to derive
a closed set of equations for these variables resulting in tractable approximations for the
computation of high dimensional sums and integrals in probabilistic models [136]. There
exist different methods to approach the mean field theory [10]:
In the variational approach, the true intractable distribution is approximated by a tractable
one, which is factorised in the sites, thus making the different spin variables statistically
independent from each other. The probability has to minimise a certain distance measure,
e.g. the Kullback-Leibler distance (the relative entropy).
The Field Theoretic approach replaces discrete expectations over the random variables
by integrals of auxiliary field variables to be able to use better performing approximation
methods for these integrals, like Laplace transformation or saddle-point methods.
In this section we want to focus on the approach introduced by Plefka et. al [137]. Here
they used the method of Taylor expansion around zero coupling, the so-called small cou-
pling expansion, of the Gibbs free energy in a Sherringtion-Kirkpatrick (SK) model. The
aim is to approximate the unknown distribution (i.e. the parameters) from which the
known magnetisations arise. Another derivation was given by Georges and Yedida [138]
and was extended by Morcos et al. [9] for the Potts model with q > 2.
In this approach they introduce an additional parameter α ∈ [0, 1], which affects cou-
plings g, and allows to interpolate between independent variables (for α = 0) and the
original model (for α = 1).
The Gibbs potential, cf. Eq. (4.31), with the perturbed HamiltonianH(α) is given by






























The Gibbs potential is approximated with the Taylor expansion. More precisely, the in-











It turns out that the zeroth and first order terms of the expansion
G(α) = G(0)(α) + G(1)(α) = G(0) + dG(α)
dα
|α=0 α+O(α2) (4.37)
reveal the mean field theory and will be explained below. The second order term corre-
sponds to the TAP free energy, what we refer to in Section 4.3.2.
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The first part of Eq. 4.37 denotes the Gibbs potential for a non-interacting system. In statis-
tical mechanics, the free energy equals the average energy (average Hamiltonian) minus
the entropy. If α = 0, the average energy is removed during the Legendre transformation,
so the negative entropy of the marginals for the uncoupled spins remains:




































The terms for A = q are removed to include only independent variables (cf. Section 4.3.1).
The first order of Eq. (4.36) results in the average coupling term in the Hamiltonian (the








If Equations (4.38) and (4.39) are plugged into Eq. (4.35) the first order approximation of
the Gibbs potential is found. Recalling Eq. (4.32) the local fields h can be determined by














The second derivative (cf. Eq. (4.34)) yields the inverse covariance matrix and can be






= (C−1)ij(A, B) = −gij(A, B). (4.41)
This last equation provides the solution for the problem of parameter inference in only
one single step, instead of iterative schemes for parameter fitting. This approach of mean
field approximation allows to fit the one- and two-site marginal of the model P(σ) with
the empirical frequencies fi(A) and fij(A, B) from data samples. In order to determine
the couplings g, the empirical covariance matrix
Cij(A, B) = fij(A, B)− fi(A) f j(B) (4.42)
has to be inverted. The matrix inversion with a time complexity ofO(L3) is much simpler
to compute than the maximum likelihood where the parameters have to be fitted itera-
tively with an exponentially large number of steps to calculate the partition function and
its derivatives.
To use only the zeroth and first order to determine the parameters is called the naive
mean field approach.
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Thouless-Anderson-Palmer Equation
As already implied in the last section, the second order expansion of the Gibbs potential
(cf. Eq. (4.36)) leads to the TAP equations. TAP was introduced in 1977 by Thouless,
Anderson, and Palmer [139] derived for the Sherrington-Kirkpatrick (SK) model in high















The added term, the so called Onsagar correction term, can be interpreted as the effect of
fluctuations of a spin variable on its magnetisation resulting from their impact on neigh-
bouring spins [139].





















The differentiation with respect to mj (cf. Eq (4.34)) yields
(C−1)ij(A, B) = −gij(A, B)− 2mi(A)mj(B)gij(A, B)2. (4.45)
Solving for couplings g we get
gij(A, B) =
√
1− 8mi(A)mj(B)(C−1)ij(A, B)− 1
4mi(A)mj(B)
. (4.46)
This can be used to retrieve the local fields h in Eq. (4.44).
4.3.3 Scoring Schemes in DCA
For DCA in a biological context, different scoring schemes have been derived for the pre-
diction of sequence structures, reviewed in [132]. In [9, 127] the Direct Information (DI)
was introduced, which is equivalent to the MI score (Section 4.2). Instead of using the






gij(A, B) + hi(A) + hj(B)
)
(4.47)






fi(A) · f j(B)
)
. (4.48)
This score is invariant with respect to the choice of gauge fixing (cf. Section 4.3.1), the
resulting score is always the same.
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The Frobenius norm (FN) of the coupling terms gij is given by∥∥gij∥∥2 = √∑
A,B
gij(A, B)2. (4.49)
Here, the choice of the gauge fixing method is important. The most appropriate variant is
the zero-sum gauge, which minimises the FN [127].
To overcome a bias due to phylogeny and undersampling the authors of [118] introduce
the average product correction (APC) of a norm rank.
This correction for the Frobenius norm was used in several studies [128, 140], after Jones
et. al. [129] introduced the idea of using the APC of the 1-norm for couplings.
In [141], this scoring alternative was also used for the inference of RNA structures and






The inferred interactions indicate sites in close proximity within the sequence structure.
These physical contact predictions can be used to derive secondary and tertiary structures
of the molecule, as illustrated in Figure 4.4. For example in [141], the authors used the
tool Nucleic Acid Simulation Tool (NAST) [142], which is a coarse-grained modeller for
sequence structures. Feeding NAST with 2d and 3d contact predictions as input, allows
the algorithm to simulate structure folding, resulting in coarse-grained structure mod-
els. Final candidates are picked according to the lowest folding energy and are used to
ascertain all-atom structures.
FIGURE 4.4: Inferring RNA structures with evolutionary couplings. In-
teracting nucleotides in close proximity within a sequence structure may
co-evolve in order to retain a functional RNA. These interactions can by de-
tected in MSAs with DCA methods and allow to reveal the RNA secondary




In the chapter before, we discussed methods to infer evolutionary constraints from multi-
ple sequence alignments of homologous sequences. The sequences originate from a com-
mon ancestor and possess information about domains which are crucial for the viability
of the regarded organism. Thus, these domains remain conserved since changes lead to
impaired structures and functionality, and consequently to a lower fitness, and might not
be competitive with the established species.
Within the MSA, only viable sequences are included. The more dominant a geno– or phe-
notype is, i.e. the higher the contribution to the gene pool, the more likely it is to observe
a certain species, and hence to find it within the MSA. This makes it a challenging task to
quantify and to comparatively assess functionally important sites without this sampling
bias. Moreover, intermediate forms are overpowered and never or hardly observed, but
may give insights on which configurations or which particular positions are the bottle-
neck to keep a vital organism.
Several approaches have been presented to characterise functional domains and structure-
function-relations with mutation experiments, and quantifying RNA-RNA or RNA-Protein
interactions [143–146]. Most of these classical approaches are time-consuming or require
substantial experience and equipment.
In this chapter, we first present the method of Smyth et al. [8], the Mutational Interference
Mapping Experiment (MIME). This method enables the detection of regions and struc-
tures crucial for certain functions of non-coding RNAs. With a single experiment it is pos-
sible to quantify the impact that a mutation has on these functions for each nucleotide.
The samples, which are conducted in MIME experiments, are sequenced with next gener-
ation sequencing (NGS). The succeeding data preparation and analysis, performed with
the software tools presented in Chapter 6, considers properties and challenges due to the
next generation sequencing process.
Therefore, we briefly explain NGS, focusing on the Illumina sequencing techniques.
5.1 Mutational Interference Mapping Experiment
The mutational interference mapping experiment (MIME) [8], is a time- and cost-efficient
experimental method to detect domains and structures important for RNA function at
single site resolution. In MIME, a target RNA is randomly mutated, selected by function,
physically separated, and sequenced using NGS, as depicted in Figure 5.1.
The mutation frequencies in the functionally selected vs unselected pools contain infor-
mation about the function and structural commitment of each single nucleotide within
the analysed RNA. The analytical approach allows the recovery of quantitative parame-
ters and permits the identification of base pairing partners directly from the sequencing
data.
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Mutagenesis














FIGURE 5.1: Experimental pipeline for MIME: random introduction of mu-
tations into an RNA target, physical separation of functional from non-
functional RNA, and quantification of RNA mutations in each population
using NGS. Figure adapted from [8].
The input for the analysis of the MIME-generated data consists of base counts at each po-
sition, respectively for the pool of functionally selected- and the non-selected sequences.
The nucleotide occurrences are derived after mapping the NGS reads to the reference, the
original wild type sequence. These counts are translated into a quantitative effect on the
function associated with each particular mutation m at each nucleotide position i, relative
to the functionality of the wild type. To assess the statistical significance of that effect, a
resampling-like procedure is applied that can be obtained from the given input data.
Since the experimental procedure (sequencing and reverse transcription) may introduce a
substantial number of falsely detected mutations, these errors need to be quantified. Con-
trol experiments, conducted without mutagenesis, allow to determine the error rates. The
relative effects are corrected for these errors and a signal-to-noise ratio can be derived.
In a last step, the results are evaluated according to several quality criteria, including the
statistical significance and signal-to-noise ratio.
In a first in vitro application, the binding domain of the HIV-1 Pr55Gag protein to the 5′
region of the viral genomic RNA could be identified with MIME at single nucleotide res-
olution and the RNA structural elements promoting this interaction [8]. Subsequently,
MIME could be adapted to in cellulo experiments [12], defining elements within the 5′ re-
gion of the HIV-1 genomic RNA that regulate viral genomic RNA production, as well as
motifs required for gRNA packaging into virions, explained more fully in Chapter 7.
In the following section we describe the mathematical background of the MIME frame-
work, as an example with the affinity of an RNA binding to a certain protein, as presented
in [8].
5.1.1 Relation between Nucleotide Frequency and Relative Kd Values
The basic reaction scheme underlying the competitive binding experiment that separates
RNA by binding affinity is shown in Fig. 5.2. In the graphic, the differentially colored ?
symbols indicate the presence of a particular mutation at a specific nucleotide position in
the RNA. The mass-action kinetics describing this experiment are given by:
























FIGURE 5.2: Reaction scheme underlying the competition experiment that
selects RNA by binding affinity (left). Bound- and unbound RNAs are sepa-
rated, prepared for sequencing and sequenced to obtain mutation frequen-





w(i) · B · kon,w(i)− Sbw(i) · koff,w(i) (5.1)
d
dt





m(i) · B · kon,m(i)− Sbm(i) · koff,m(i) (5.3)
d
dt
Sum(i) = −Sum(i) · B · kon,m(i) + Sbm(i) · koff,m(i) (5.4)
d
dt
B = Sbw(i) · koff,w(i) + Sbm1(i) · koff,m1(i) + . . . + Sbm3(i) · koff,m3(i)
− B · (Suw(i) · kon,w(i) + Sum1(i) · kon,m1(i) + . . . + Sum3(i) · kon,m3(i)) , (5.5)
where Sbw(i) denotes the concentration of bound RNA carrying a wild type base at nu-
cleotide position i and Suw(i) denotes the concentration of unbound wild type RNA. The
subscript m represents the three possible mutations m ∈ {m1, m2, m3} and indicates the
presence of one of the mutations at nucleotide position i. The parameter B denotes the free
protein, and koff(i), kon(i) describe the respective rates of dissociation and association.
In a steady state condition, i.e. if there is sufficient time to obtain a binding equilibrium,
the left hand side (the rate of change) of the equations becomes zero. Solving one equation












which denotes the relative impact of a particular mutation m at position i in the RNA
sequence on the binding affinity in relation to the wild type. The Kd value describes the






Unfortunately, the numbers of bound and unbound sequences S are not known. Instead
we derive NGS reads R, subject to errors X (sequencing and RT-errors). In order to ac-
count for this noise, we have to consider the relation between "sequence numbers" S and
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"reads" R: For any mutant nucleotide m at nucleotide position i, the number of NGS reads









where Xm→n(i) is a random variable that denotes the number of sequences that are in
fact nucleotide m, but were falsely detected as some other base n. Likewise, Xn→m(i)
is a random variable indicating the number of sequences that were originally some other
nucleotide n, but were falsely detected as m. Parameter ν denotes the normalisation factor,
i.e. the relative titration, if applied. It guaranteed that equal amounts of protein-bound
and –unbound sequences were used in the NGS machinery.
The error probability κ(i) is assumed to be very low (for Illumina < 10−3) and may not be
vastly different for the distinct types of transitions n → m. Thus, false detections, which
do not affect the concentration significantly can be neglected, resulting in
Sm(i) ≈ Rm(i)
ν




Assuming that the noise X is multinomially distributed, i.e. Xw→m ∼ M(Sw, κw→m), the
expectation value for the number of mutations m can be estimated with
E(Xw→m(i)) = Sw(i) · κw→m(i) ≈ Rw(i)
ν
· κw→m(i), (5.11)
where κw→m(i) denotes the probability of falsely detecting a wild type residue at position
i as mutation m.
To estimate the error probability κw→m(i), experiments with unmutated RNA are con-
ducted in parallel. This means, the number of sequences with mutations are zero (for
both selected and non-selected samples), i.e. Sm1(i) = Sm2(i) = Sm3(i) = 0 ∀ i. Thus, the
(falsely) detected mutations of reads R arise from the RT- and sequencing procedure.
Substituting the expected noise of Eq. (5.11) into Eq. (5.9) and plug Eqs. (5.9) and (5.10)












Note, that the above described procedure yields one single point estimate for each pos-
sible mutation at each nucleotide position within the RNA of length L for the impact on
the function. Although it is possible to infer the effect from the simple method above, it
is not possible to assess the statistical certainty of these estimates, unless vast numbers of
repetition experiments are performed. However, this procedure is expensive and time-
consuming.
Instead, the statistical certainty of the relative Kd estimates is inferred with a method
based on resampling, inherent in the data.
The basic idea is to determine relative impact of a mutation Km,w(i, j) for each combination
of nucleotide positions i 6= j, where the first residue i is mutated and the second residue
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FIGURE 5.3: Schemec of the resampling procedure. Each pair of positions
(i, j) yields a Kd estimate (left). The resampling distribution for KdmKdw (i) can
be visualised (right, top) and statistical tests can be performed in order to
detect significantly increasing or decreasing binding affinity of a mutant in
relation to the wild type with a certain p-value (right, bottom). Graphics
taken from [8], Supplementary Figures.
j is in the wild type configuration, thus having no effect on the relative Kd estimate. This
allows to re-estimate the effect of a mutation m at position i N-times, with N ≤ L− 1.
Since less sequence fragments will cover both i and j the further j lies away from i (see
Fig. 5.3, left panel), the procedure is highly similar to a classic jack-knife resampling pro-
cedure. Here, a re-estimation is performed each time after removing one individual from
the pool of samples. The resampling will then give a non-parametric and unbiased prob-












The resampling scheme also allows to estimate the probability of falsely detecting a wild
type residue at position i as some mutant m (cf. Section 5.1.2) with statistical properties:




where N denotes the number of positions j 6= i, if the position pairs (i, j) have sufficient
read coverage. Thus, following the resampling scheme for the relative Kd, we can esti-
mate a confidence range for the error probability κw→m(i).
Note: The coefficient of variation of the error rate distribution is assumed to be small in
the selected and unselected sample, respectively. Hence, a more reliable estimate can be
inferred (law of large numbers). This justifies the use of the estimate E (κw→m(i)) for the
error correction of all Kd estimates instead of the single error resample κw→m,w(i, j).
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5.1.4 Quality Criteria
For each position i and mutation m it is possible to resample a distribution of effects with
the scheme explained above. Different criteria can be applied in order to filter these esti-
mates to improve the result.
Evaluable Signal
One of the filters conducts the signal-to-noise ratio, which can be assessed with the data
from the control experiments also used for the error correction. For each of the N resam-
ples for position i and mutation m we compute the signal-to-noise ratio by
Dm,w(i, j) =
Rm,w(i, j)
ν ·E(Xw→m,w(i, j)) ≈
Rm,w(i, j)
Rw,w(i, j) · κw→m,w(i, j)
≈ Rm,w(i, j)
Rw,w(i, j) ·E(κw→m(i)) . (5.15)
If the ratio is below a user-supplied threshold, both in the bound and unbound samples,
the corresponding Kd estimate Km,w(i, j) is discarded. If the signal is below the threshold
at either the bound or unbound samples, the respective estimate is tagged as either be-
ing a lower– or upper estimate of Km,w(i, j). In this case, the value of the median of the
estimate distribution Km,w(i, ?) is assigned. This has the following reason: If a mutation
strongly decreases the Kd (increases the function), all sequences carrying this mutation
may be bound. None, or too little amounts of sequence may remain unbound. Thus,
Km,w(i, j) may not be accurately determined and may in fact be lower than estimable.
Coverage
For the resampling procedure, only positions j are evaluated where the total number of
sequence fragments covering both i and j has at least a user defined percentage of the
maximum coverage (middle panel in Fig. 5.3, left). Secondly, the total number of reads
that have to be available (middle panel in Fig. 3, left) has to exceed a "minimum coverage"
value. Both criteria together ensure that each resampling is based on a sufficient number
of reads and thus provides meaningful estimates.
Number of resamplings
After applying the filters above, a certain number of estimates Km,w(i, j) remain and give
rise to an empirical distribution (see Fig. 5.3, left (lower panel) and right (upper panel)).
A minimum number of resamplings is required in order to reconstruct the empirical dis-
tribution with sufficient confidence (see Fig. 5.3, lower panel on the right).
Statistical test
The statistical test can subsequently be performed on the resampling distribution (Fig 5.3,
lower panel on the right): To test whether a mutation at position i significantly increases
the Kd/decreases the function, i.e. H0 : Km(i) ≤ 1,H1 : Km(i) > 1, the raw p-value (=
probability of type I error/false rejection of the null hypothesis) can be computed accord-
ing to:
p−m(i) =
#Km,w(i, ?) ≤ 1
#Km,w(i, ?)
, (5.16)
where # denotes the number of estimates and ? indicates all N positions j that pass the
quality criteria above. To test if mutation m at position i decreases the Kd/increases the
function, the p-value is calculated according to:
p+m(i) =
#Km,w(i, ?) ≥ 1
#Km,w(i, ?)
. (5.17)
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Note, that any threshold (e.g. 2-fold increase/decrease, etc.) can be tested. When sev-
eral nucleotide positions i are assessed, test corrections need to be performed, e.g. the
Benjamini-Hochberg false discovery rate method (BHFDR) [147].
There is a significant impact of mutation m at nucleotide position i, if the corrected p-
value does not exceed a certain significance level α (false positives), which is also given
by the user.
5.1.5 Detecting Functional Structures with MIME
The MIME framework is not only able to detect single positions which play an important
role for the function. It also allows to assess whether this residue is directly involved in
the function (e.g. forming the binding site) or indirectly, i.e. as part of the structure within
the RNA which is necessary for the function, more specifically, if it forms a base pair with
another position.
The main concept for detecting interacting base pairs is illustrated in Fig. 5.4.
FIGURE 5.4: Two nucleotides interact in their wild type configuration in a
way that is important for function (left). Single mutations at either position
disrupt this interaction (middle) and thus impair RNA function. When both
positions are mutated in a particular way, the interaction, and thus RNA
function may be restored. Graphic taken from [8], Supplementary Figures.
If two positions i and j play a role for the function in their wild type configuration, certain
single mutations at either position i or j would disrupt the function of the RNA (cf. the
methods above). If these two positions are not interacting, the mutations of both posi-
tions may still impair the function, probably with an even stronger effect. In the case of
correlation of these positions, certain configurations of double mutations of i and j may
compensate the disrupting consequence of the single mutations. If the two positions are
forming a base pair in the wild type configuration, which is important for the functional
structure, the replacement with a base pair in the double mutant constellation may keep
the structure and hence the function.
A measure for these interactions is called epistasis and is extensively elucidated in Chap-
ter 3.3. The aim is to detect positive sign epistasis, which allows us to infer pairs of inter-
acting sites where mutations at both sites i and j may restore a function that is impaired
by the single mutants.
Epistasis E for the mutation pair (m1, m2) at the respective nucleotide positions (i, j) can
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be computed according to
Em1,m2(i, j) = log
(




where Km1,m2(i, j) denotes the relative Kd value for a RNA that harbours mutation m1 at
nucleotide position i and mutation m2 at nucleotide j. Km1,w(i, j) denotes the relative Kd of
an RNA that exhibits mutation m1 at position i and has the wild type residue at position
j. Likewise, Kw,m2(i, j) denotes the relative Kd of an RNA that has the wild type residue
at nucleotide position i and mutation m2 at nucleotide position j.
If there is no epistasis (E = 0), the two residues are independent. An positive epistasis
value E > 0 means that the double mutant restores the function, whereas an negative
epistasis value E < 0 means that the double mutant amplifies the impact on the function.
Note, that Eq. (5.18) yields one point estimate for each pair of mutations m1, m2 at each
pair of nucleotide positions (i, j). To assess the statistical certainty of these epistasis esti-
mates, the resampling procedure, introduced in Section 5.1.3, has to be adapted. The basic
idea is as before: In order to attain a probability distribution of the epistasis for positions
(i, j), we compute epistasis values for the triplet of positions(i, j, k), where the first- and
second residue (i, j) are mutated respectively and the third residue k is in the wild type
configuration (see Fig. 5.5). This allows us to recompute the epistasis value for the pair
FIGURE 5.5: Resampling scheme for epistasis estimates. In order to re-
sample the epistasis values Em1,m2(i, j) for the mutation pair m1, m2 at nu-
cleotide positions i, j, values are computed for the triplet of positions (i, j, k).
Position i and j are mutated to m1 and m2, respectively, and position k
is wild type. Each triplet yields one epistasis estimate (bottom). Graphic
taken from [8], Supplementary Figures.
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(i, j) M times, with max(i, j) < k < min(i, j):
Em1,m2,w(i, j, k) = log
(




In order to accommodate the resampling method we will have to extend the previously
described method (previous section) to be able to compute the relative Kd values for any
triplet of positions.
As before, the number of selected/unselected sequences S are not known, but we have the
number of NGS reads R instead, which are subject to errors X (sequencing and RT-errors).
The RNA sequence number S harboring two mutations at positions i and j respectively
and has a wild type residue at position k is related to the RNA read numbers R by
Sm1,m2,w(i, j, k) ≈ Rm1,m2,w(i, j, k)− Xw→m1,m2,w(i, j, k)
− Xm1,w→m2,w(i, j, k)− Xw→m1,w→m2,w(i, j, k). (5.20)
Assuming a multinomial distribution of the noise as before, we get:
Km1,m2,w(i, j, k) ≈
Rum1,m2,w(i,j,k)
Ruw,w,w(i,j,k)
− Υum1,m2,w(i, j, k)
Rbm1,m2,w(i,j,k)
Rbw,w,w(i,j,k)
− Υbm1m,m2,w(i, j, k)
, (5.21)
with








· κ?,w→m2,?,w(i, j, k). (5.22)
The following conditions hold for both the bound and unbound fractions:
κw→m1,?,w(i, j, z) ≈ κw→m1,?(i, j), κ?,w→m2,?,w(i, j, k) ≈ κ?,w→m2,?(i, j).
The parameters κw→m1,? and κ?,w→m1 denote unconditional probabilities, namely one po-
sition was falsely detected as a mutant, regardless of the second position (indicated by
the ?), thus the estimated error probabilities from Eq. (5.14) may be used. The same con-
ditions holds for the error probability of detecting 2 mutations: κw→m1,w→,m2,w(i, j, k) ≈
κw→m1,w→,m2(i, j), which is approximated by
κw→m1,w→,m2(i, j) ≈ κw→m1,w(i, j) · κw,w→,m2(i, j). (5.23)
Accordingly, the relative effects can be derived:
















44 Chapter 5. Quantifying Functional Constraints
5.2 Next Generation Sequencing
The samples, which are used in MIME experiments, are sequenced with Next Genera-
tion Sequencing (NGS). The term NGS comprises a variety of sequencing technologies
processing millions of DNA fragments in parallel in one cycle. This allows for high-
throughput sequencing with a drastic reduction of costs in comparison to classical se-
quencing techniques. The individual procedures from the DNA sample to the sequence
can be grouped into three steps:
1. Library preparation
2. Clonal, parallel DNA amplification
3. Sequencing
In the following, we will briefly present these steps of the sequencing process, based on





FIGURE 5.6: Library preparation. Genomic
DNA is randomly fragmented and sequencing
adapters are ligated to both ends. Figure adapted
from [148].
Library preparation
The NGS library preparation (seen in Fig-
ure 5.6) starts with the random fragmen-
tation of the investigated DNA or reverse
transcribed RNA (cDNA) sample. Se-
quencing adapters, which are necessary
for subsequent steps, are ligated to both
ends of the fragments. The fragments are
amplified with PCR and purified on gel.
Cluster Generation
The library is loaded into a flow cell, which
contains a lawn of oligo nucleotides bound
to the surface. These oligos are comple-
mentary to the library adapters, in order
to capture the fragments by hybridisation,
and function as primers for the amplifica-
tion. Each bound fragment is amplified
building clonal clusters through bridge
amplification, as seen in Figure 5.7.
Sequencing
A flow cell containing millions of unique clusters is now loaded into the sequencer for au-
tomated cycles of extension and imaging. Illumina’s method of Sequencing-by-Synthesis
(SBS) uses the technique of Cyclic Reversible Termination (CRT), illustrated in Figure 5.8.
In each cycle, DNA polymerase, and modified nucleotides are added to the flow cell.
The four distinct nucleotides are marked with different fluorescent colours and contain a
reversible terminator. All four nucleotides are added and synthesised by the DNA poly-
merase to the complementary DNA strand, which is attached to the flow cell surface.
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FIGURE 5.7: Cluster amplification. The fragments of the library are loaded
into a flow cell and bind to complementary oligos on its surface. The frag-
ments are amplified via bridge aplification building clonal clusters. Figure
adapted from [148].
Only one nucleotide per cycle can be incorporated, since the terminator group is blocking
the further synthesis.
After non-attached components are washed away, the synthesised fluorescent nucleotides
are excited with a laser and the emitted colour of each cluster is captured in an image.
Through imaging techniques, the respective nucleotide is recognised for each cluster.
In the end of the cycle, the terminator and fluorescence are removed and the next cycle
starts. Nucleotide by nucleotide, the sequence for each cluster is determined at the same
time.
incorporation of one modied nucleotide per cycle laser excitation sequence determination
laser
FIGURE 5.8: Base calling. During each sequencing cycle, the four labeled
reversible terminators, and DNA polymerase are added to the flow cell.
Only one nucleotide is appended to one emerging double strand per cycle,
because of the terminator. After laser excitation, the emitted fluorescence
from each cluster is captured and and the corresponding base is identified.
Cycle by cycle, the sequences for each cluster are determined in parallel.
Figures adapted from [148, 150].
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5.2.2 Paired-End Sequencing
FIGURE 5.9: Paired-end sequencing with NGS.
After the clonal clusters are sequenced from the
first end, the clusters are regenerated and the
complementary sequence is determined starting
from the other end. The paired-end reads are
aligned to the reference sequence. Figures taken
from [149].
Depending on the biological issue, NGS
facilitates the possibility of choosing be-
tween single-read sequencing and paired-
end sequencing. The latter involves the se-
quencing from both ends of the DNA frag-
ments (depicted in Figure 5.9), leading to
double the amount of reads in the same
time and effort of library preparation. For
further data analysis, the reads are aligned
to a reference genome (but can also be
used for de-novo assembly). The major
advantages of aligning the read pairs are
higher accuracy of the alignment and the
improved possibility of detecting single
site nucleotide variants (SNVs), as it is de-
sired in the MIME experiments explained
above. Furthermore, it is possible to detect
insertions and deletions (indels), as well as
to remove PCR duplicates, which often oc-
cur during library preparation.
5.2.3 Quality Scoring
The determination of the single nu-
cleotides in each cycle of the sequencing
procedure, together with all other steps
during next generation sequencing and
further data processing, have an impact on
the quality of the data. A very common
score to measure the base calling accuracy
of a sequencing platform is the Phred qual-
ity score (Q score). Historically, Phred
scores were used to measure the quality
of base calls with Sanger sequencing, com-
prising metrics such as peak resolution
and shape to derive the quality by comparing results to multivariate lookup tables [151].
Although, the metrics for NGS platforms are different from those for Sanger sequencing,
the algorithm for the Phred scoring scheme could be adapted to particular chemical prop-
erties [152]. The quality score lookup tables are constructed by exploiting the relevant
parameters of a large empirical dataset of known accuracy.
The Q score is logarithmically related to the error probability P of predicting a wrong
base [151, 153]: Q = −10× log10(P).
Thus, the Q score denotes the base call accuracy, i.e. the probability of a correct base call.
For example, if a Q score of 30 is given, the corresponding error probability is 1 in 1000
times to detect a wrong nucleotide, meaning 99.9% accuracy of the base call. In Table 5.1,
Q scores and their corresponding accuracy are given.
A Q score of 30 is often considered a minimum quality score threshold for NGS. The de-
tected sequence is reliable and most likely contains no error. Considering a lower quality
score, for instance Q = 20, and hence a given error probability of 1 in 100, would mean an
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TABLE 5.1: Quality scores and corresponding base call accuracy
Phred quality score Probability of incorrect base call Accuracy of base call
10 1 in 10 90%
20 1 in 100 99%
30 1 in 1000 99.9%
40 1 in 10000 99.99%
50 1 in 100000 99.999%
incorrect base every 100 nucleotides, i.e. the sequencing reads most likely contain errors.
The range of the scores depend on the sequencing technology and the base calling al-
gorithm. Recent Illumina sequencing reads can reach a quality score up to 41 for raw,
unprocessed reads.
5.2.4 FASTQ
The resulting NGS reads are written into FASTQ files. For each read, the FASTQ file
includes four lines containing
• a header starting with symbol "@", containing an identifier that usually gives infor-
mation about the sequencing run and the cluster
• the nucleotide sequence read by the sequencer
• the symbol "+", (optionally followed by additional descriptions)
• a corresponding quality score for each base call represented by ASCII characters





The encoding of the quality score with ASCII characters in a FASTQ file depends on the
sequencing platform, illustrated below [154].
The example read above has a Phred+33 quality score (Illumina 1.8+): The stretch of As in






In Chapter 5, the Mutual Interference Mapping Experiment (MIME) [8] has been pre-
sented. Briefly recapitulated, in MIME RNA is randomly mutated, selected by function,
physically separated, and sequenced using NGS.
For the evaluation, the sequencing data has to be mapped to the reference sequence. With
the resulting mapping files it is possible to extract the nucleotide frequencies for each po-
sition, which will be used to conduct the data analysis of the mathematical framework
presented in the previous chapter.
This pipeline requires several computational steps, which are implemented in efficient
and flexible software. The first tool described here uses mapped reads in SAM format to
generate count data files containing position-wise nucleotide frequencies. These files are
the input for the second software, MIMEAnTo [11], allowing to analyse the target RNA
with regard to its function.
6.1 SAM to Counts
In order to evaluate the resulting MIME data after sequencing to infer functional impor-
tant regions within the assayed RNA, they have to be preprocessed in a workflow, illus-
trated in Figure 6.1. The fragmented RNA sequences conducted in MIME experiments are
in FASTQ format after sequencing. They need to be demultiplexed, trimmed, and mapped
to the reference sequence to enable the inference of position-wise nucleotide frequencies.
The particular steps are described below.
Sequencing
ref seq
AA       AC         ...         UU
...          ...          ...         ...
...   3425651  ...      3452
...   3424321  ...      2852
:::          :::          :::          :::
...       4321      ...   852974...          ...          ...          ...
 i     j 
pair 
 .      .
8    35
8    36
 :      :


















FIGURE 6.1: Pipeline of preprocessing the sequencing data. The sequenc-
ing output is in FASTQ format (two files for the read pairs) and contains all
samples. The samples need to be separated according to their barcode. Se-
quencing adapters have to be removed, accompanied by quality clipping.
After mapping to the reference sequence, the resulting SAM files serve as
input for the counting routine. The resulting output are text files containing
position (–pair, or –triplet) –wise nucleotide frequencies.
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6.1.1 Preprocessing: From Sequencing Output to SAM Files
The output of the sequencing machine are genome fragments (reads) in FASTQ format,
introduced in the NGS Section 5.2. In the MIME protocol, the different samples are tagged
with barcodes during library preparation. The sequenced fragments for all samples are
pooled in one large file and need to be demultiplexed according to their barcoding. An
example demultiplexing tool is Novocraft’s "NovoBarcode".
The sequencing procedure requires certain adapters, which were ligated to the genome
fragments. They were sequenced along with the fragments and have to be removed. At
the same time, quality clipping is necessary in order to get clean reliable data and to
achieve a solid result. A tool for adapter trimming would for example be "Trim Galore!"
(Bioinformatics, Babraham Institute), which also filters nucleotides according to a given
quality threshold. For instance, a threshold with Phred+33 quality scoring of 30 would
correspond to a base call accuracy of 99.9% (cf. Section 5.2.3).
The fragmented, reverse transcribed RNA is sequenced from both sides of the donor
sequence, resulting in paired-end reads, which are placed in two separate FASTQ files.
The information, which paired reads belong together, and the relative direction on the
reference sequence are known. The trimmed read pairs are aligned to the reference se-
quence with a mapping tool which allows multiple mismatches, such as "NovoAlign"
from Novocraft, as multiple mismatches are expected in the randomly mutated data. The
resulting output files are in Sequence Alignment/Map Format (SAM).
6.1.2 Implementation
The original preprocessing program was based on python scripts created in connection
with the MIME method [8]. However, the routines required several hours for big data
sets, especially for processing covariational information. Hence, we considered it worth-
while to implement the software in a more efficient way using C++14, also adjusting and
extending further filtering options. The complexity of the program is O(M · (rd) + (Ld)),
with M giving the number of paired-end reads in the SAM files, r the approximate read
length, L the length of the reference sequence and d the dimension for the count routine
(considering single sites = 1d, position pairs = 2d, position triplets = 3d). The first term
qualifies the (rd) increments for M reads, with M usually running into millions. The sec-
ond term describes the output routine, and is rather negligible.
With our implementation, we were able to achieve an immense speed up. To exemplify,
with a number of around 2.5 million read pairs of an average length of 85 nucleotides
each and a total length of 535 nucleotides of the reference sequence, we could reduce the
runtime for the 1d case from 36 minutes with the python script to 7 seconds with the new
implementation. For the 2d case, the time could be reduced from 32 hours to 39 seconds.
The programs were launched on a MacBook Pro (2015) with 2.5 GHz Intel Core i7 and 16
GB RAM.
The program is called from the command line with
sam2counts <reffile> <samfile1> <samfile2> <outfile> <dimension> <qualiThreshold>
and requires the following parameters
reffile (string) path to reference sequence file in fasta format
samfile1 (string) path to first SAM file of the mapped paired reads
samfile2 (string) path to second SAM file of the mapped paired reads
outfile (string) path to output file containing the counts in tsv format
dimension (int) either 1, 2, or 3 for the counting dimension
qualiThreshold (int) threshold for the quality score
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Despite quality clipping during the data preparation, the quality threshold was deemed
necessary in this routine. The reason is, that it is usually assumed that the quality of a
sequence drops towards the ends of the fragments. Hence, nucleotides with bad quality
are trimmed until a good quality is reached. However, it may also happen that a drop
of quality occurs within the sequence and these nucleotides of bad quality remain in the
read. Therefore, we check for the quality of all nucleotides, since this requires only one
additional operation per iteration.
The program can be divided into three procedures. The read pairs are imported and pre-
filtered, the cohesive sequences of a read pair are merged to one read with certain rules,
and finally, the reads are counted for each position and nucleotide and written into the
output file. The procedures will be described in particular in the following subsections.
Prefilter
After importing the reference sequence, the read pairs are imported from the two SAM
files and processed one by one. Each alignment line of a SAM file contains 11 mandatory
fields of essential mapping information, and a variable number of optional fields. An
example of an alignment line is given below:
FCC1073ACXX:6:1101:17307:2200#AGTCAAAT/1 0 HIV1_535 22 70 94M6S * 0 0
TCTGAGCCTGGGAGCTCTCTGGCTAACTAGGGAACCCACTGCTTAAGCCTCAATAAAGCTTGCCTTGAGTGCTCAAAGTAGTGTGTGCCCGTCTTGTGGT
abbccccegggggiiiiihhhhiiiihhiihhhgfghghfffiiiffhiiiifihicfhffhhiiiheggdgeeeceeadb_bddccbbbaaaBBBBBBB
PG:Z:novoalign AS:i:64 UQ:i:64 NM:i:0 MD:Z:94
Only those fields, which are used for further filtering are explained here.
In a first filtering step, both sequences are checked for their mapping status. We consid-
ered multiple conditions to assess mapped reads:
• The second field in a line contains a bit flag. If the fourth bit is set, the fragment is
unmapped.
• The fourth field gives the left most mapping position. To be mapped, the positions
must be > 0.
• The so called CIGAR string in the sixth field contains important mapping informa-
tion. If these are unavailable, indicated by a "∗", we regard the read as unmapped.
Read pairs are only considered if both sequences are mapped. Side note: The example
above complies with none of these criteria (indicated in red), hence this read is mapped.
For further processing, the CIGAR string, the mapping positions, the nucleotide sequence
(10th field), and the qualities in ASCII representation (11th field) are extracted.
The CIGAR string includes different operations to describe the mapped read. Regions
with alignment matches are denoted by "M", which does not necessarily mean that the
nucleotides agree with the reference sequence. An alignment match includes sequence
matches and mismatches. Deletions are denoted by the character "D", insertions by "I",
and soft clipped regions, which can not be mapped, are indicated by the character "S". The
preceding numbers in front of the respective characters denote the amount of consecutive
nucleotides to which this operation applies. In the example above, the CIGAR string
contains 94M6S, i.e. 94 positions are matching the alignment and six positions could not
be mapped. For construction of the ultimate read, only matching regions are considered.
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Merging
The matching sequence pair is merged to one single read for the count routine. However,
these reads may contain regions or single positions which are ignored, because they do
not fulfil the following requirements.
First of all, a symbol in the sequence other than the four bases A, C, G, and T is invalid.
This is also the case for nucleotides where the quality score is smaller than the given
threshold.
The pair of sequences can either be distinctly mapped to the reference such that there is a
region in between, which is not covered by the reads, as illustrated in Figure 6.2, top.
FIGURE 6.2: Mapping of paired reads to the reference sequence. The upper
mapping shows the two sequences which are aligned distinctly such that
a region in between is not covered. Below, the two fragments are aligned
such that they cover partly the same region.
In this case, the nucleotides of the matching positions of both aligned sequences are sim-
ply added to the merged read. In case indels occur in between the matching regions, they
are also treated as not covered regions.
However, the mapped sequences may also overlap, as seen in Figure 6.2, bottom. For
the overlapping region, different cases are contemplated to decide for the incorporated
nucleotide. If the two nucleotides are equal, which may be either the wild type of the
reference sequence or a mutation, the respective nucleotide is added to the read. If they
differ, but one of the sequences contains the wild type, the other one is considered as se-
quencing error and the wild type is chosen for the read. This applies also, if the one wild
type nucleotide is given and the second symbol is invalid. If the two nucleotides disagree,
but both differ from the reference (including being invalid) the position is neglected. An
overview of the different cases is given in Figure 6.3.
Counting
The constructed new read is evaluated according to the given dimension parameter.
In the case of single site variation (dimension = 1), the respective nucleotide count is
incremented by one for each incorporated position. After iterating through all reads, the
nucleotide occurrences (#) of all positions are written into the given output file, seperated
by tabulator:
pos #A #C #G #T
For the 2d case, co-occurring nucleotides for each position pair are counted. The resulting
output contains the frequencies in the following format:
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FIGURE 6.3: Different cases to handle overlapping reads. If at least one of
the two mapped sequences carries the wild type base at the aligned posi-
tion, it is incorporated into the merged read for this position. If one of the
sequences carries a different base than the reference, it is only considered
as true mutation in the merged read if both sequences carry the same base,
or if an insertion or deletion (represented by "_") is present in the other se-
quence. If both sequences carry different bases or one of them is invalid
(indicated by "N"), the position is ignored in the merged read.
pos1 pos2 #AA #AC #AG #AT #CA #CC ... #GG #GT #TA #TC #TG #TT
As example, the column "#AG" contains the number of reads which span the two respec-
tive positions and comprise the nucleotide "A" at the first position and the nucleotide "G"
at the second position.
Similarly, the reads for a dimension of 3 are counted for each triplet of positions and nu-
cleotide co-occurrences and written into the output file:
pos1 pos2 pos3 #AAA #AAC #AAG #AAT #ACA ... #TGT #TTA #TTC #TTG #TTT
6.2 MIMEAnTo
The MIME Analysis Tool (MIMEAnTo [11]) processes MIME generated data, allowing to
analyse RNA with regard to its function. The mathematical concepts of the workflow are
broadly explained in Chapter 5.1.
The input consists of base counts at each position, obtained from the next-generation se-
quencing reads after mapping to the reference sequence and counting, as described in the
previous section. Each input data set, corresponding to one experimental set up, consists
of the counts for the selected and unselected samples of the mutant library, and counts for
the selected and unselected samples of the control library conducted without mutations.
The counts are translated into "raw" quantitative effects of mutations on a certain function
relative to the wild type configuration. These effects are computed for all three possible
mutations at each sequence position. Since the NGS reads from the MIME experiment
are confounded by errors, introduced during library preparation and sequencing, error
correction and statistical assessment are essential.
MIMEAnTo has a wizard-like graphical user interface, guiding through the data analysis
procedure in three steps:
• data input and assessment
• correction of errors due to reverse transcription and sequencing
• quantification of raw effects and quality filtering
The results can be plotted as publication ready graphics.
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6.2.1 Implementation
MIMEAnTo is a cross-platform software, implemented in C++ using the boost library,
and the Qt framework for the graphical user interface. The plots are generated with gnu-
plot. The program is available as standalone binary executable for different operating
systems or can be compiled using the source files (download from https://github.com/
maureensmith/MIMEAnTo).
All interim settings will be saved in a text file (project.txt) in the given result directory.
This file will be created after initialising the project in the GUI and updated during the
workflow. It can be used to reload the project.
Project Initialisation
FIGURE 6.4: Step I of the analysis pipeline: Initialising/loading the project
and check of the mutation rates. Screenshot of MIMEAnTo.
In the first step of the analysis-pipeline (corresponding UI in Figure 6.4), the project is
initialised with the following mandatory parameters in the above-placed rows:
• a result directory, where all intermediate and final results are saved
• a reference sequence, either in fasta format, or a text file containing "position,base-
number", where the nucleotides are provided by numbers following the convention:
A = 1, C = 2, G = 3, U = 4
• the data directory where the reference sequence and the subdirectories ("1d" and
"2d") with the respective count files are stored
Furthermore, the sample data sets have to be added to the data table. Each sample set
has to be named, e.g. indicating the different experiment conditions like a particular pro-
tein concentration. As mentioned above, the sample set is composed of the count files for
selected and unselected samples from a wild type– and mutant library, respectively. The
associated barcodes have to be entered to the respective fields. In addition, the forward
and backward primers can be clipped from the examined sequence.
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The creation (or loading) of the project invokes a first plausibility check. A boxplot show-
ing mismatch frequencies summarised over all positions for each sample library is created
using the provided 1d data. The plot allows the user to assess whether the data looks
reasonable at first sight. For example, mutant libraries should have a higher mismatch
frequency than their corresponding wild type counterpart.
Error Estimation
FIGURE 6.5: Step II of the analysis pipeline: Error estimation (top) and
assessment of the differences between errors of selected and non-selected
samples (bottom). Screenshots of MIMEAnTo.
The evaluated data contains noise, which has been introduced during library prepara-
tion and sequencing. In order to approximate the true mutation frequency in the mutant
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libraries more precisely, the errors have to be corrected according to Equation (5.14) de-
rived in the mathematical framework of MIME in Chapter 5.1:




The error estimate for each position and mutation is resampled with the covariational (2d)
data of the non-mutated control samples for each of the selected and unselected sample
pool. The single error estimates can be quality filtered using the parameter percentage
of maximum coverage. This threshold reassures a considerable depth for the resampling:
Position pairs are only regarded for the error calculations if they reach a minimum read
coverage.
The error plot on the first tab in MIMEAnTo, seen in Figure 6.5 on the top, shows the
mean mutation rates (+IQR) per position for each sample of the project. The second tab,
in Figure 6.5 on the bottom, comprises the coefficient of variation between all samples
belonging to either the selected or non-selected pool, i.e. giving a measure of how similar
the errors among the samples are. On the basis of the coefficient of variation, the user
can decide to compute a single error estimate for all samples in one pool for further eval-
uations, or to consider the errors independently. Joining the errors of a pool with a low
coefficient may achieve a better statistical foundation for the error estimate.
In addition to error correction, the estimated error rates will be used in subsequent anal-
ysis to asses a signal-to-noise ratio, i.e. the approximated true mutation signal vs the
expected noise.
Kd Estimation and Quality Filtering
In the third step, relative effects of mutations can be calculated (or imported, if already
computed). The raw Kd values for each position pair (i, j) and mutation m at position i











The effect of mutation m at sequence position i is resampled by considering the covaria-
tional data. The number of reads spanning positions i and j 6= i, comprising mutation m
at position i and the wild type nucleotide at position j are denoted by Rm,w(i, j). Rw,w(i, j)
gives the number of reads with the wild type residue for both positions. The error cor-
rection term is given by the expected error probability of falsely detecting a wild type at
position i as a mutant m (E(κw→m(i)), calculated in the previous step.
Several features describing the data are calculated along with the effects and can be used
to filter the sample set to improve the quality of the results. Moreover, a p-value for
each estimate is computed applying the significance test described Eq. (5.16) and (5.17) in
Chapter 5.1.4. These quality criteria can be set by the user and will be briefly explained
below:
% of maximal coverage
Determines the depth of resampling, i.e. only position pairs exceeding a minimum cover-
age are regarded for Kd estimation, similar to the error estimation before. The minimum
coverage is assessed with respect to the position with the maximal read coverage. This
quality criteria will be important for filtering when the coverage is in general very high.
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FIGURE 6.6: Step III of the analysis pipeline: Estimation of the raw effects
(Kds) and quality filtering. The upper plot shows the position-wise resam-
pled Kd estimates (log2) for each of the three possible mutations in boxplot
format. The different mutations are colour-coded (A C G U). The lower plot
contains the median of the maximum effect (log2) for each position. Signif-
icant effects are denoted with ∗ in the colour of the respective mutation.
Screenshot of MIMEAnTo.
minimum coverage
Determines the depth of resampling, i.e. only position pairs exceeding a minimum cov-
erage are regarded for Kd estimation. Here, the minimum coverage is determined in ab-
solute numbers. This criterion will be important for filtering when the coverage is rather
moderate.
minimum signal-to-noise ratio
A signal-to-noise ratio Dm,w(i, j) is computed for each pair of positions (i, j) and for each
mutation m according to Equation (5.15) in Chapter 5.1.4. It is recommended to use a
signal-to-noise ratio of at least 2 in MIMEAnTo (the true signal is at least twice the ex-
pected error). Otherwise, the noise might be falsely considered as signal. A threshold > 2
should be chosen with caution to find a balance between data quality and quantity.
minimal number of estimable Kds
For the statistical ascertainment, it is important to assure a sufficient sample size: p-values
will only be computed for mutation m at position i, if the number of resamplings exceeds
the threshold provided here.
alpha
Level of significance. Kd estimates are marked as significant if the p-value is < α.
significance threshold
The significance test ascertains position-wise mutations, whether they have an significant
effect. The threshold can be adjusted to determine mutations that have a significant, and
if desired, strong effect, i.e. if a mutation at the regarded position affects the function more
than c-fold.
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minimum mutation rate
Filtering resamples with low mutation rate, in case of heterogeneous mutation rates within
the samples. The parameter gives the magnitude for the mutation rate, e.g. minMutRate
= 4, means that the min. mutation rate is 10−4.
The Kd estimates are plotted after the quality filtering, as seen in Figure 6.6:
1. All mutational effects





, of all three mutations per
sequence position i as candlesticks (median + IQR) in different colours for the re-
spective mutations (A C G U). The ∗ above or below the given wild type letter of the
position denotes if the effect significantly increases or decreases the Kd.
2. Maximal mutational effects
The lower plot highlights the mutation with the strongest effect (positive or nega-





. Again, the ∗ indicates if the effect is signifi-
cant and the colour-coding identifies the respective mutation.
The plots can also be saved in two distinct files, either for the whole sequence or an user
defined region.
Output
Plots All plots of the above described steps can be saved in the subdirectory path_to_
results/plots. The user can choose to save the plots as eps- and/or pdf-file with an (op-
tional) suffix for the filename.
Tables Tabular result files of the Kd computation are exported as csv-files in the user de-
fined result directory. Optionally, the user can give a suffix for the files, to generate several
results with different parameter settings.
Information about all mutational effects are written into the tab seperated file "Position-
WiseKdEstimates" containing the following data:
• position
• wild type base w (A = 1, C = 2, G = 3, U = 4)
• max. effect base mmax (A = 1, C = 2, G = 3, U = 4)
• for each base (mutation) m = A, C, G, U
– median KdmKdw
– p-value for KdmKdw
– #resamplings for KdmKdw
– #lower estimates for KdmKdw
– #upper estimates for KdmKdw
– 5th percentile of KdmKdw estimate
– 95th percentile of KdmKdw estimate
The tab separated file "PositionWiseMaxKd" contains the information about the mutation
with the maximum effect for each position:
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• position
• wild type base w (A = 1, C = 2, G = 3, U = 4)
• max. effect base mmax (A = 1, C = 2, G = 3, U = 4)
• median KdmmaxKdw
• p-value for KdmmaxKdw
• #resamplings for KdmmaxKdw
• #lower estimates for KdmmaxKdw
• #upper estimates for KdmmaxKdw
• 5th percentile of KdmmaxKdw estimate
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FIGURE 7.1: The HIV-1 5′ UTR folds into a series
of structural domains regulating the viral life cy-
cle: TAR, PolyA, PBS and SL1-3. Figure extracted
from [12].
In Chapter 2, we examined the replication
cycle of HIV-1 in detail and how the ge-
nomic RNA of the virus is involved in each
of the steps. We have seen, that the vi-
ral gRNA encodes nine (poly–)proteins. In
addition to its coding capacity, the HIV-1
gRNA contains numerous regulatory ele-
ments. These elements interact in complex
ways to control key steps of the HIV-1 life
cycle including transcription, translation,
export, packaging and reverse transcrip-
tion. Particularly, the 5′ UTR and the be-
ginning of the Gag coding sequence com-
prise a high concentration of these regu-
latory sequences, as presented in detail in
Section 2.3.1. This highly structured region
contains a series of functional domains, as
a reminder shown in Figure 7.1: the trans-
activation region (TAR) element for tran-
scription, PolyA for polyadenylation, the
primer binding site (PBS) for reverse tran-
scription, SL1 containing the dimer initiation site (DIS) for gRNA dimerisation, SL2 with
the splice donor (SD), and SL3 considered hitherto as the major packaging domain.
The regulatory elements are essential for the viral replication. Hence, they give promis-
ing targets for new antiviral drug design [155]. First achievements in this direction have
been attained for the case of Hepatitis C virus (HCV) patients, which could be successfully
treated by functionally inhibiting regulatory ncRNA [6]. However, the current knowledge
about regulatory mechanisms in HIV is limited and needs to be further explored. For the
analysis of functionally important RNA, high-resolution and quantitative methods are re-
quired.
In Chapter 5.1, we explained the Mutational Interference Mapping Experiment (MIME)
in detail. MIME is a powerful tool for the detection of functional constraints on molecular
level in a one-step evolutionary process, revealing functionally and regulatory important
regions. A first application of MIME was done by the authors in an in vitro experiment,
mapping the binding site of the human HIV-1 Pr55Gag protein on the viral gRNA and
modelling RNA structure motifs that are crucial for protein binding [8].
In this chapter we present our results for the adaption of MIME for in cell experiments [12],
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defining RNA elements within the 5′ UTR of the HIV-1 gRNA that are important for vi-
ral replication in cells. After transferring the biological context of the application from in
vitro to in cellulo, we briefly explain the experimental procedure. The resulting data out-
put is evaluated according to the mathematical background explained in the subsequent
section. Finally, we will present the detected regulatory motifs and discuss the results of
the analysis.
7.1 From in vitro to in cell Experiments
The recently deveopled method MIME (cf. Chapter 5.1) has been used for an in vitro
experiment to determine functional regions within genomic RNA in single site resolu-
tion [8]. More precisely, the authors could determine the Pr55Gag protein binding sites on
the viral gRNA of HIV-1 in SL1 and SL3. The complex of Pr55Gag and the viral gRNA
is recognised as a major determinant of the packaging process, where the dimerised vi-
ral RNA is packed into new emerging virions. In fact, it has been shown, that with the
absence of gRNA, Pr55Gag binds to any nucleoacid molecule (even without the protein
binding domain), suggesting that RNA plays a structural role during virus assembly [156,
157]. Still, the HIV-1 gRNA is selectively packaged into nascent virions, which arouses the
curiosity on how the virus can differentiate between RNAs, putting a great importance on
the comprehension of signals controlling the packaging process.
We applied MIME to in cell experiments to answer the question, whether the motifs bind-
ing to Pr55Gag found in vitro also pertain to the native cellular environment. Moreover, we
were interested whether additional signals, e.g. binding sites for other proteins or nucleic
acids, are relevant for effective packaging.
In addition, the experimental setup allowed to explore the regulatory impact of the 5′
UTR on intracellular gRNA production.
The experimental design will be described in the following, depicted in Figure 7.2: The
proviral genome is randomly mutated using error prone PCR, and subsequently cloned
into a genomic RNA expression vector. The vector was modified to serve only as expres-
sion vector for the mutation libraries by containing:
• restriction sites for the cloning of the mutant libraries
• a substitution in the start codon of gag to prevent Gag expression
• a stop codon to prevent Tat protein expression
• a deletion in env (for biosafety)
The structural and enzymatic precursor proteins, Gag and Gag-Pol, and accessory pro-
teins Tat and Rev, were expressed from a separate packaging vector. The vectors were
co-transfected into human 293T cells, leading subsequently to the transcription and pack-
aging of mutant RNAs. The segregated functionally selected and unselected RNA pop-
ulations in cells and virions, respectively, were extracted and reverse transcribed. After
amplification of the viral cDNA and the input DNA plasmids, the material was frag-
mented, barcoded, and eventually sequenced using Illumina HiSeq2500. The resulting
NGS data was analysed using the MIMEAnTo software [11], introduced in Chapter 6.
By varying the functional selection criteria, we obtained two distinct maps of regulatory
RNA controlling intracellular gRNA production and gRNA packaging, respectively: For
the gRNA production, comprising the steps from the transfected genomic material to the
transcribed gRNA in the cells, we found three regulatory motifs. For the packaging of
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FIGURE 7.2: In cell Mutational Interference Mapping Experiment (in cell
MIME). The proviral genome was randomly mutated using error prone
PCR, and subsequently cloned into a gRNA expression vector. Gag and
Gag-Pol were expressed from a separate expression plasmid. The mutant
library and Gag/Gag-Pol expression plasmid were transfected into 293T
cells. Transcripts of mutant RNAs were functionally sorted by the viral
and cellular machinery. Viral RNA present in cells and virus was reverse
transcribed. Viral cDNA and the input DNA plasmid was amplified, frag-
mented, barcoded, sequenced, and analysed using the MIMEAnTo soft-
ware. Figure extracted from [12].
gRNA, including the steps from the gRNA in cytoplasm to the successfully assembly of
virions with packed gRNA, two regulating signals could be detected. Strikingly, a hex-
amer sequence within 5′ PolyA regulated both gRNA production and packaging, reveal-
ing the cellular polyadenylation machinery as a dual regulator of HIV-1 replication.
In the next section, we are going to elaborate the mathematical evaluation leading to these
results.
7.2 Analysis of in cell MIME Data
Akin to the method explained in Chapter 5, the goal is to infer quantitative effects of each
mutation m at each nucleotide position i on gRNA production and packaging, obtained
from the generated NGS output.
Mutations with a strong impact on the respective function indicate which regions are
involved in the particular process. A schematic depiction of viral gRNA production and
packaging in the cellular environment is shown in Fig. 7.3. For simplicity, we focus only
on two viral strains here, termed wild type w and mutant m. The analysis easily extends
to arbitrarily many viral strains (as in the experiment).
In this example, mutant m and wild type w differ only at a single position i. The mutation
has a biophysical impact on at least one of the assayed functions. The following system
of ordinary differential equations describes the mass-action kinetics of intracellular and
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FIGURE 7.3: Dynamical system of RNA populations in cells and virions.
Gag expression plasmids are co-transfected with library expression plas-
mids. The gag expression plasmids produce transcripts that are subse-
quently translated into Gag polyproteins that may form a packaging com-
plex with viral RNA, or be directly targeted to the cell surface to form
nascent virions. Library expression plasmids produce transcripts with rate
kprodw/m. This unbound viral RNA may either bind to a packaging complex
with rate konw/m or be degraded intracellularly. RNA that is bound to the
packaging complex may either dissociate with rate koffw/m or be packed into
nascent virions and released with rate krel. Figure taken from [12], Supple-
mentary Figures.








































m · krel. (7.6)
The dynamical system can be explained as follows: The subscripts for the rates and con-
centrations describe for which species they apply, with w for the wild type and m for
the mutated RNA. The number of transfected library expression plasmids are denoted by
Spl. They produce transcribed gRNA with rate kprod, which we denote here as the free,
unbound RNA Su. With an association rate of kon, the free gRNA forms a bi-molecular
complex with the available packaging protein P(t), and is degraded with rate δu. The
concentration of the bound RNA is labelled with Sb and releases the complex with rate
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koff, or degrades with rate δb. The RNA which is bound to the complex gets shuttled to
the cellular surface, packed into nascent virions, and released to the extracellular space
with rate krel, resulting in the concentration of RNA in virions Svirus.
7.2.1 Relation between Nucleotide Frequencies and the Effect on intracellular
gRNA Production
In order to compute the impact of mutations on gRNA production, we deduce the muta-
tion frequencies of the viral RNA present in the cell. A fraction of the produced gRNA is
packed and released into viruses, which could in theory distort the true observed amount
of produced RNA. For example, a mutation that increases packaging and lowers the pool
of cellular RNA, could be misinterpreted as a mutant that decreases the gRNA produc-
tion. However, the following observation motivated us to assume that the number of viral
RNA in cells is not significantly altered by the packaging process, and thus not biasing the
prediction of production efficacy: The packaging process is mediated by the Gag-protein
(and possibly other cellular factors). However, the number of Gag molecules in virions
vastly exceeds the number of RNAs. A dimer of gRNA is packed into a virion together
with about 5000 Gag-proteins [158]. Two contradicting scenarios could explain this ob-
served stoichiometry:
1. scenario: The number of RNA molecules is much smaller than the number of avail-
able proteins.
2. scenario: The majority of intracellular viral RNAs is not bound to the complex or
packaged into virions.
The first scenario implies a very low number close to depletion of viral RNA in the cell.
Hence, a very low competition between the different RNA strains would occur. With an
excess of proteins the majority of RNAs would be packed into virions, especially due to
the mentioned fact that Gag can bind to any RNA for the assembly of new virions. In this
case, hardly any RNA could be extracted from the cells, or would yield very low counts.
However, we clearly observe plausible signals for RNA in cells. Moreover, the results for
packaging in the in cell analysis closely resemble the regulatory region found for the Gag
binding experiments in vitro under competitive conditions. Both facts strongly argue for
the second scenario, i.e. there is an excess of free over bound RNA inside the cell, i.e.
Su >> Sb and thus Scell ≈ Su, at least in our assay.
We thus can deduce the number of total cellular RNA (unbound and bound to the pack-
















m · kprodm − Sum · δu. (7.8)
Splw/m denotes the number of plasmids that carry the wild type or mutant RNA. We assume
that the plasmids are stable, hence constant (this assumption is not necessary to derive the











) kprodm · Splm
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. (7.10)
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Computing the fraction of mutants in the DNA library divided by the fraction of mutants
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We assume that the transfection efficacy is identical between the wild type and the mutant






















for arbitrary time t.
In the equation above, the term Kprodm denotes the decrease of the gRNA production
caused by mutation m relative to the gRNA production efficacy in the wild type w and
will be used to assess the impact of mutations on the gRNA production efficacy. The term
will be increased (Kprodm > 1), whenever a mutation decreases gRNA production.
Depicting only the maximal impact of all three possible mutations mmax(i) for each site i
helps to identify regions which are important for gRNA production (as seen in the result
Figure 7.6).





where mutation m is only considered if it has a significant impact on the production at
nucleotide position i. If there is no mutation with a significant impact, all possible muta-
tions at that position are evaluated.
7.2.2 Relation between Nucleotide Frequencies and the Effect on Packaging
If binding to the packaging complex is fast with respect to the other processes, gRNA
production, and release, we can assume a quasi-equilibrium in Equations (7.2) and (7.5).






w = 0 and get after rearranging
Suw(t) =




Sbm · (koffm + δb + krel)
konm · P(t)
. (7.14)
We retain the two assumptions from above: The number of RNAs in the cell Scell is given
by the sum of bound and unbound RNAs Su + Sb, and the vast majority of RNAs in the
cell is unbound. Hence, Su >> Sb and thereby Scell ≈ Su. Thus, we get
Scellw (t) =




Sbm · (koffm + δb + krel)
konm · P(t)
. (7.16)
In addition, we assume that the quasi-equilibrium is reached quickly, allowing us to ap-
proximate the bound RNA by a constant, i.e. Sb(t) ≈ constant. It therefore matters to
the inference of the relative effect on packaging that sufficient time has passed for this
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approximation to be accurate. Under these assumption Eqs. (7.3) and (7.6) can be solved
analytically, i.e. the RNA accumulating in virions is given by
Svirusw (t) ≈ krel · t · Sbw (7.17)
Svirusm (t) ≈ krel · t · Sbm. (7.18)
Dividing the fraction of mutant RNA in the cell by the fraction of mutant RNA that accu-
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· k
off
m + krel + δb
konm
, (7.19)
meaning the ratio of mutation frequencies in the cells vs virions is constant. Additionally,
















Thus, the ratio of mutant frequencies in the cell versus the mutant frequencies in the viri-
ons determines the effect of that mutation on viral genome packaging. The term will be
increased (Kpackm > 1), whenever a mutation decreases gRNA packaging.
In order to identify regions that are important for packaging, one may also depict the im-
pact of the mutation mmax(i) that has a maximal impact at position i, akin to the evaluation
of maximal effect on gRNA production above (seen in the result Figure 7.10).
7.2.3 Error Correction
The detected nucleotide counts inferred from the NGS output for the DNA library-, the
intracellular-, and the viral RNA respectively, are confounded by errors introduced dur-
ing sequencing and reverse transcription. These errors are corrected analoguously to the
derivations in [8], extensively explained in Chapter 5.1.2. The relation of sequences S and








This relation holds for the DNA library, the cellular RNA, and RNA packed into virions.
The fraction of RNA that is sequenced is denoted by 0 < ν < 1 and Xw→m(i) denotes the
number of wild type residues which are falsely detected as mutant m, i.e. the absolute
sequencing error. For simplicity, we have skipped the time index t as it is irrelevant for
the subsequent arguments.
As in [8], we assume that the absolute sequencing error X is multinomially distributed,
i.e. Xw→m(i) ∼ M (Sw(i), κw→m(i)). The expectation value for the number of mutations
m of the multinomial distribution is trials× success probability. In our context this means
that
E (Xw→m(i)) = Sw(i) · κw→m(i) ≈ Rw(i)
ν
· κw→m(i), (7.23)
68 Chapter 7. MIME applied to in cell Experiments with the HIV-1
where κw→m(i) denotes the probability of falsely detecting a wild type residue at position
i as mutation m.
Using the multinomial model, we then correct the mutation frequencies in the reads for


















The error probability κw→m(i) can be computed with the data of control experiments,
where the RNA is not mutated and will be described in Section 7.2.5.
7.2.4 Statistical Assessment of Effects
To evaluate whether a mutational perturbation of the gRNA production or the packaging
process is significant, we apply the same resampling statistics as presented in Section 5.1.3,
instead of the single estimates derived above.
In brief, the core idea is to determine the effects Kprodm,w (i, j), respectively K
pack
m,w (i, j) for
each combination of positions i and j, where the first residue i is mutated and the sec-
ond residue j is in the wild type configuration. This allows to re-estimate the effect of a
mutation m at position i N-times (all pairs of residues with j 6= i).
The resultant equations for recomputing mutational effects on gRNA production are








and for the packaging, we derive:








The resampling gives a non-parametric and unbiased probability distribution of the esti-
mates above.
The statistical test can subsequently be performed on this resampling distribution:
To test whether mutation m at position i increases Kprod (decreases gRNA production)
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where # denotes the "number of estimates" and ? indicates that all positions j are evalu-
ated that pass the quality criteria (cf. Section 7.2.6).










The analogous scheme can be used to compute the significance of the effect on packaging.
Note, that one can test any threshold c ≥ 0 (e.g. 2-fold increase/decrease), whereas the
choice c = 0 allows to detect all positions that have any effect on the respective function.
In [12], we chose c = | 1N ∑i log2 K˜m(i)|, i.e. the average log-effect over all positions, which
allows to test for strong effects.
For Kprodm , we used c = 0.42 and for K
pack
m we had a threshold of c = 0.41, corresponding
to ≈ 1.3-fold changes.
All reported p-values were corrected by the false discovery rate (FDR)-based method of
Benjamini-Hochberg.
There is a significant impact of mutation m at nucleotide position i, if P < α. Here, we
used α = 0.05.
7.2.5 Estimation of Error Probability κ
For the estimation of the error probability κw→m, control experiments were conducted
where the RNA is not mutated, thus Sw,m(i, j) = Sm,w(i, j) = 0.
In the same manner as it is shown in Chapter 5.1.3, the re-sampling scheme allows us to
compute statistical properties of the error probability:




where N denotes the number of co-varying positions j that have sufficient read coverage,
spanning i and j. Thus, along the same lines as the re-sampling scheme for the relative
effects on gRNA production and packaging, we can estimate a confidence range for the
error probability κw→m(i).
7.2.6 Quality Criteria
For each pair of reads Rm,w(i, j) and Rw,w(i, j) we assessed its respective signal-to-noise
ratio in the corresponding RNA pool (DNA, cell and virion) according to:
Dm,w(i, j) ≈ Rm,w(i, j)Rw,w · κw→m,w(i, j) . (7.31)
If the ratio is below the user-supplied threshold in both samples (DNA library versus cell
and cell versus virion), the corresponding estimate (Eqs. (7.26) or (7.27)) for this position
pair is discarded.
If the signal is below the threshold in only one of the samples, the respective estimate is
tagged as either being a lower- or upper estimate of the mutations’ effect and assigned
the value of the median effect estimate on RNA production or packaging respectively, as
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explained thoroughly in the Section 5.1.4 in the MIME chapter and Section 6.2.1 in the
Software chapter.
For our analysis, we chose a threshold of 2 for the signal-to-noise ratio.
We only evaluated Equations (7.26) and (7.27) for positions j where the total number of
sequence fragments covering both i and j was at least 50% of the maximum coverage.
For determining p-values, at least 300 re-estimates had to fulfil the quality criteria.
7.3 Results
7.3.1 Data Description
The entire 5′ UTR and the beginning of the Gag coding region fold in to a series of func-
tional domains, regulating key steps of the HIV-replication cycle [51, 53, 57], including
intracellular gRNA production and packaging into nascent virions. Therefore, the first
∼ 500 nucleotides of the viral HIV-1 gRNA were targeted for the functional analysis. The
in cell MIME procedure was performed using six mutant libraries conducted in three in-
dependent experiments (two mutant libraries per experiment). The segregated RNAs in
the cells and virions were physically separated and sequenced. Additionally, the DNA
which was transfected into the cells was sequenced. The three types of samples were de-
rived from both the wild type and the mutant libraries. The sequences of the non-mutated








































































(B) Error corrected substitution rates of the mu-
tation libraries.
FIGURE 7.4: A: Box and whisker plot of substitution frequencies (log10) for
wild type library (red) and mutations libraries (green and blue) in DNA,
cell and virus raw data of three different experimental replicates. The mu-
tation rates for the mutation libraries are significantly higher than for the
wild type controls (P < 0.01 respectively, Wilcoxon rank sum test). B: Box
and whisker plot of the error corrected mutation frequencies (log10) for the
mutation libraries in DNA, cell and virus raw data of three different ex-
perimental replicates (with two libraries per experiment). Figures adapted
from [12], Supplementary Figures.
In total, we aligned 80 million sequences to the reference genome, finding 1.08 × 108
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mutations from 2.15 × 1010 nucleotides. Raw substitution rates were found to be sig-
nificantly higher in the mutant library compared to the wild type control experiments
(Figure 7.4a), demonstrating that biologically relevant mutations could be clearly distin-





































Error corrected mutation rates from A to G
FIGURE 7.5: Box and whisker plot of the er-
ror corrected mutation frequencies (log10) of nu-
cleotide A to G for the mutation libraries in DNA,
cell and virus raw data of three different experi-
mental replicates. The A to G mutation frequen-
cies in cells are significantly higher than in DNA
and virus (P < 0.01, Wilcoxon rank sum test).
Figure taken from [12], Supplementary Figures.
We were able to use the substitution fre-
quencies in the wild type control to ob-
tain error-corrected mutation frequencies,
thus eliminating any biases from errors in-
troduced during library preparation and
sequencing. As seen in Figure 7.4b, er-
ror corrected mutation rates were similar
across all six independent libraries from
the three independent experiments (Fig-
ure 7.4b) and were highly reproducible
for all classes of mutations. They con-
tinuously decreased from DNA (median
= 4.8 × 10−3), cellular gRNA (median =
4.2 × 10−3) to virion gRNA (median =
3.3 × 10−3) indicating purifying selection
with the proceeding viral lifecycle.
Surprisingly, we observed a consistent ele-
vation of A to G mutations within the cel-
lular gRNA compared to the input DNA
and the RNA extracted from the virus (p-
value < 0.01), clearly recognisable in Fig-
ure 7.5. These cellular A to G substitutions
were enriched at 5′ AA 3′ and 5′ UA 3′ di-
nucleotides and seemed to cluster at unpaired adenines in close proximity of double
stranded RNA structure. Although we have no clear biological explanation for this phe-
nomenon, it is reminiscent of editing characteristics of the dsRNA adenosine deaminases,
ADAR1 or ADAR2 [159, 160]. Despite being an interesting conspicuity, it is most likely
unrelated to the investigated processes of gRNA production and packaging. Therefore,
we omitted this class of mutation in our analysis.
7.3.2 Regulation of intracellular gRNA Production
First, we focused on the detection of regulatory motifs affecting the viral gRNA produc-
tion in the infected host cell. The mutation frequencies of the initially transfected DNA
library was compared to the frequencies of the viral RNA extracted from the cells. As
derived above, the effect of a mutation m at position i can be expressed by the relation of
the mutation frequencies in the DNA versus the cell, denoted as Kprodm (i) (cf. Eq. (7.12)),
and in addition, statistically ascertained. Kprodm (i) > 1 means that the mutation decreases
gRNA production and stability. Conversely, Kprodm (i) < 1 identifies mutations that in-
crease gRNA production and stability.
The analysis revealed three distinct regions strongly and significantly affecting the pack-
aging process, both in a positive and negative way, mapped to TAR, PolyA and SL2,
respectively. The regions are highlighted in Figure 7.6, showing the log effect on gRNA
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production log2K
prod
m (i) for the whole sequence.


















FIGURE 7.6: In cell MIME discovery of RNA
motifs regulating HIV-1 gRNA production:
log2 K
prod of the mutation with the maximal ef-
fect on RNA production for the 5′ UTR and Gag
coding region (smoothed with a linear, two-sided
convolution filter of width 2). Functional do-
mains are indicated with coloured boxes below
the graph. Black triangles above indicate sig-
nificant effects. Three regions with significant
(P < 0.05) and strong (log2 K
prod ≥ 1 or ≤ −1,
gray dotted line) effects are highlighted with red
circles. Figure extracted from [12].
Unsurprisingly, gRNA production is pos-
itively regulated by the motif found in
TAR, indicated by the strong depletion of
TAR mutants in the cellular gRNA, clearly
seen in Figure 7.7. This is concordant with
its known allocation of binding sites for
the Tat protein and the cellular factor P-
TEFb [161–166]. The mapping of the sig-
nals for TAR on the structure in Figure 7.7
shows a substantially stronger effect of the
apical part of the stemloop compared to
the distal portion of the stem. Again, this
agrees with different studies showing that
the distal portion of TAR is less important
for gene expression compared to the apical
portion [167, 168].
The second signal affecting gRNA produc-
tion was found in 5′ PolyA. Here, an ac-
cumulation of mutated gRNA was found
inside the cell in relation to the trans-
fected mutant frequency in the DNA li-
brary, unveiling a negatively regulating
role of PolyA. The 73AAUAAA78 hexamer
within the apical loop was identified as the
precise signal when mapped to the struc-
ture (see Figure 7.8). The effect on the pro-
TAR
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FIGURE 7.7: Regulatory motif for gRNA production in TAR. Mutations
with maximal effect on log2 K
prod mapped on TAR structure. Box and
whisker plot of the effect of each class of mutation on log2 K
prod. Black
dot shows median, box shows IQR, whiskers show extremes (1.5× IQR).
Mutation classes are colour coded: red = A, green = C, blue = G, yellow =
U. Figure extracted from [12].
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duction includes all mutations within this signal, except for the mutant at position 74 from
A to U, pointed out in the boxplot in Figure 7.8. As the motifs AAUAAA and AUUAAA
are recognised as common cellular polyadenlyation signals [169], the results indicate a








60 65 70 75 80 85 90





















FIGURE 7.8: Regulatory motif for gRNA production in 5′ PolyA. Mutations
with maximal effect on log2 K
prod mapped on PolyA structure. For expla-
nation of the plot see Fig. 7.7. Figure extracted from [12].
The third signal mapped to SL2, shown by a lower mutation frequency in this region
within the cells than in the transfected DNA, thus implying a regulatory activity of SL2
in gRNA production. Interestingly, mutations disrupting gRNA production mapped pre-
cisely to the U1 snRNA binding site 289GGUGAGU295 (Figure 7.9), and includes all types
of mutations. This observation was surprising, as one might expect that disrupting the
splice donor site, and with that eliminating the splicing of viral RNAs, would enrich un-
spliced gRNA in cells. Nevertheless, the opposite effect is observed here, and our data
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FIGURE 7.9: Regulatory motif for gRNA production in SL2. Mutations with
maximal effect on log2 K
prod mapped on SL2 structure. Mutations impair-
ing gRNA production cluster to the U1 snRNA binding site. For explana-
tion of the plot see Fig. 7.7. Figure extracted from [12].
7.3.3 Regulation of gRNA Packaging
Following, we determined regulatory motifs affecting the packaging of intracellular gRNA
into nascent virions. This process comprises multiple molecular events, including the for-
mation of a protein-RNA packaging complex, its transport to the cell surface, and the
packaging and assembly of viral particles, hence presumably involving several regula-
tory components. The relation of the mutation frequencies in the RNA extracted from the
cells and the virions can be used to detect the effect of mutation m at position i on pack-
aging, given by Kpackm (i) (cf. Eq. (7.20)).
Kpackm (i) > 1 means that the mutation decreases gRNA packaging, and K
pack
m (i) < 1 in-
volves a mutation that increases packaging.
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We were able to find two strong and significant signals mapped to 5′ PolyA and SL1-SL3,
both important for the packaging process, as seen in Figure 7.10 showing the log packag-
ing defect log2K
pack
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FIGURE 7.10: In cell MIME discovery of
RNA motifs regulating HIV-1 gRNA packaging:
log2 K
pack of the mutation with the maximal ef-
fect on RNA packaging for the HIV-1 5′ UTR
and Gag coding region (smoothed with a lin-
ear, two-sided convolution filter of width 2).
Functional domains are indicated with coloured
boxes. Black triangles above indicate significant
effects. Two regions with significant (P < 0.05)
and strong (log2 K
pack ≥ 1, gray dotted line)
effects are highlighted with dot red line/circle.
Figure extracted from [12].
Suprisingly, we observed that the packag-
ing signal within 5′ PolyA mapped pre-
cisely to the same 5′ PolyA sequence
73AAUAAA78 that we identified as a
strong regulator of gRNA production (Fig-
ure 7.11). Like their effect on gRNA pro-
duction, all mutations to this hexamer se-
quence impaired gRNA packaging into
virions, except for a single mutation at
position 74 from A to U, tagged in the
boxplot in Figure 7.11. Again, the fact
that the motifs AAUAAA and AUUAAA
are well known polyadenylation signals
suggests an important role for the cellu-
lar polyadenylation machinery for gRNA
packaging in addition to its influence on
gRNA production [169].
The second packaging signal spans the
SL1, SL2, and SL3 structures in the psi do-
main, as highlighted in Figure 7.12. In
the beginning of this chapter, we already
pointed out that this region was previ-
ously identified with in vitro MIME experi-
ments as the Pr55Gag binding site [8]. Con-
sequently, our results here confirm the idea
that Pr55Gag is a central player in the selection of gRNA. Yet, comparing the signal of the
in vitro Pr55Gag binding versus the results in cell directing gRNA packaging reveals differ-
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FIGURE 7.11: Regulatory motif for gRNA packaging in 5′ PolyA. Mutations
with maximal effect on log2 K
pack mapped on PolyA structure. Box and
whisker plot of the effect of each class of mutation on log2 K
pack. Black
dot shows median, box shows IQR, whiskers show extremes (1.5× IQR).
Mutation classes are colour coded: red = A, green = C, blue = G, yellow =
U. Figure extracted from [12].
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We compared the precise motifs within the stems of SL1 and SL3, since both were con-
sidered important for binding to Pr55Gag in vitro. Mapping the effects on the structures
of SL1 and SL3 in Figure 7.13 illustrates the differences. Suprisingly, the 257GCGCGC262
sequence within the SL1 apical loop, which was found to be crucial for Pr55Gag binding
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FIGURE 7.12: Regulatory motif for gRNA packaging in Psi domain. Muta-
tions with maximal effect on log2 K
pack mapped on S1, SL2 and SL3 struc-
tures. Qualitative comparison between the significant effects of mutations
on Pr55Gag binding determined by in vitro MIME (upper portion, green)
and the effects on gRNA packaging by in cell MIME (lower portion, blue).
Sites significantly affecting both are pictured red. Arrows above for in cell
and below for in vitro in the colour of the affected functional domain. Filled
arrows show significant effects in both. Figure extracted from [12].
Furthermore, mutations to the stem of SL1 and SL3 had similar effects on packaging in
cells. However, mutations of SL1 in vitro showed much more damaging impact on protein
binding that mutations to SL3.
Additionally, mutation of SL2 seems to be more critical for gRNA packaging in cells com-



















































Pr55Gag binding to gRNA in vitro





























































































FIGURE 7.13: Comparison of SL1 and SL3 MIME data. Pr55Gag binding
to gRNA in vitro vs gRNA packaging in cells. Figure extracted from [12],
Supplementary Figures.
7.3.4 Discussion
The HIV-1 life cycle is regulated in all its central steps by non-coding gRNA elements, e.g.
by providing binding sites for viral and cellular enzymes, factors, and other proteins, or
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other nucleotide molecules. Many of the crucial processes remain unexplained for now.
Yet, the discovery of unknown functional regions in the genome and their corresponding
structures, as well as resolving regulatory interactions slowly takes shape and provides a
promising opportunity for new therapeutic attempts for fighting the persistent pandemic
of HIV-1.
RNA is functionally flexible, meaning one motif can be involved in diverse (also contra-
dictive) processes. This complicates the determination of regulatory motifs with tradi-
tional truncation and deletion mutagenesis. The problem is strengthened by the fact that
often, especially in viral RNA, regulatory and coding regions overlap, which impedes the
identification of functional motifs. MIME [8, 11] provides a method to detect regulatory
regions in an unbiased fashion, which has been shown to perform well in vitro. Here, we
adapted the technique for in cell experiments, to shed light on the biological coherences
in the HIV-1 life cycle. We were able to find interconnected regulatory motifs within the
5′ UTR important for the production and packaging of viral gRNA, summarised in Fig-
ure 7.14. To our suprise, a common signal within the 5′ PolyA apical loop negatively




























FIGURE 7.14: Five regulatory elements controlling HIV-1 replication.
gRNA production is positively regulated by sequences within TAR and by
the U1snRNP binding site within SL2. gRNA production is negatively reg-
ulated by the AAUAAA motif in 5′ polyA. The U1snRNP binding site is
required for repression of 5′ polyadenylation. gRNA packaging into viri-
ons requires both the Pr55Gag binding site (SL1-SL3), and the AAUAAA
motif in 5′ PolyA. Regulatory elements are colorcoded: positive = green,
negative = red. Figure taken from [12].
One of the identified motifs controlling gRNA production allowed us to confirm the ap-
propriate performance of in cell MIME: Mutations within TAR, particularly the apical part
of the stem, had a negative impact on the ability to produce gRNA. This is conistent with
results of various studies localising binding sites in TAR for the Tat protein and transcrip-
tion elongation factor P-TEFb [170–173].
Furthermore, we discovered a motif within SL2 with an equally high impact on the pro-
duction process. Futher experiments in [12], which we omitted in this chapter, could
approve the involvement of SL2 in the regulation of gRNA production.
Mutations of the third recovered signal within the apical loop of PolyA, on the contrary,
led to an increase of gRNA production.
For the process of packaging viral gRNA into virions, we determined two distinct and
equally strong signals. The central motif loacalised at the psi domain spanning SL1, SL2
and SL3, closely coincides with the Pr55Gag binding site found in vitro [8, 52]. However,
we found out that the major signal encountered in vitro, the sequence 257GCGCGC262 in
the apical loop of SL1, was less important for gRNA packaging in cells. After all, we re-
veal that the SL1 stem including the internal loop are crucial for gRNA packaging, which
agrees with the consequence of SL1 deletion leading to severe packaging defects [64, 174].
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The second motif with strong impact on gRNA packaging matches the same hexamer in 5′
PolyA already determined as suppressor of full length gRNA production. Other studies
came to analogous results, showing that mutations within PolyA decrease gRNA packag-
ing [175, 176] and a complete deletion of PolyA has a similar effect as deleting both SL1
and SL3 [64, 176].
In summary, we could demonstrate that MIME can be applied to complex cellular envi-
ronments to infer regulatory elements within functional RNA at single site resolution. We
detected motifs in the 5′ UTR of HIV-1 regulating gRNA production and packaging, one
of which being involved in both processes. These results might be useful for further inves-





Combining MIME and DCA
Techniques: Accuracy Benchmark
In MIME, presented in Chapter 5 and applied to in cell experiments in Chapter 7, local fre-
quencies are used to infer functionally important sites and structural relationships within
non-coding RNA. The true effects of a mutation on the particular function may be con-
founded by effects that are caused by mutations at other positions in the sequence. This
is particularly the case, if the assessed position is involved in epistatic interactions.
The methods of DCA, explained in Chapter 4, derive a global maximum entropy model
to disentangle interactions in order to derive structural elements within a functional se-
quence.
In this chapter, we want to incorporate the ideas of DCA into the MIME framework to
derive a global model for describing the probability distribution for the functionally sep-
arated sequence pools of the MIME data. Instead of the position-wise frequencies, we
apply MIME methods on the probabilities of the respective sequence. The aim is to im-
prove the prediction of functional and structural constraints by combining MIME and
DCA methods. After examining the problem of intruding effects of hidden mutations, we
derive a global sequence model for the inference of mutational and epistatic effects. We
benchmark two DCA methods based on mean field approximation in order to optimise
our predictions.
8.1 Intruding Effects from Epistasis
In [177], we develop an optimised protocol for MIME experiments that considers varying
protein concentrations in the system and the choice of an optimal mutation rate. The latter
has to be large enough to be distinguishable from noise. However, concerns may arise that
with a too high mutation rate, predictions for mutational effects at certain position may be
confounded by the effects of mutations at other positions within the sequence, illustrated
in Figure 8.1.










with Kd denoting the respective dissociation constant, e.g. in a binding process, of wt =
the wild type sequence without any mutation, S = any sequence containing either a wild
type or a mutation at each position i.
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FIGURE 8.1: Confounding effects of mutations. The sequence reads (green),
which are mapped to the reference (black) comprise several mutations
(stars). If the mutations of a certain position i are evaluated locally (red
stars), they might be affected by mutations at other positions within the
sequence.









where position i has no interaction with any position j ∈ J. Positions J may confer
epistatic effects among each other.
As an illustrative example, we assume a sequence of length L = 2 and both positions are












(2) = 1, (8.4)








(2) = 2. (8.5)
In the case of no epistasis, the effect of the double mutant is simply given by the product








(2) = 2. (8.6)
When we compute relative Kd values based on the MIME output, i.e. position-wise
mutation frequencies, we focus on one base after the other, basically ignoring the pres-
ence/absence of additional mutations. Hence, instead of looking at the effect of the whole
sequence where only one position i is mutated, we take all sequences into account, which
have a mutation at position i, regardless of the remaining nucleotide composition (cf. Fig-
ure 8.1). This means, for the effect of a mutation at position 1 in the example above, we
look at the set of sequences with mutation m at position i, regardless of the rest of the
sequence: M(1) = Sm,∗ = Sm,w + Sm,m. The same applies for the apparent wild type
sequence set, consisting ofW(1) = Sw,∗ = Sw,w + Sw,m. Both sets are confounded by the
presence of mutants at position 2.
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For the case of protein in excess, i.e. RNA << protein, it can be shown that the following










· Kdwt · (1+ 2)
= Kdwt · 1.5, (8.8)
i.e. the absolute Kd estimate for the set of sequences which contains a mutation at position
i is false: KdMKdwt (1) = 1.5 6= 1 =
Kdm,w




· Kdwt · (1+ 2)
= Kdwt · 1.5. (8.9)
Again, we compute the absolute effect incorrectly, with KdWKdwt (1) = 1.5 6= 1 =
Kdw,w
Kdwt .
However, since we are inspecting the relative effect of each mutation in comparison to the






(1) = 1, (8.10)
meaning the relative effect can be determined correctly.
In summary, the following results were concluded for the case of no epistasis involving
position i:
• When protein is used in excess (binding saturation), the true relative effect is deter-
mined.
⇒ KdMKdW (i) =
Kdm
Kdw (i)
• When we are in the linear binding regimen (little protein), the true relative effect is
determined.
⇒ KdMKdW (i) =
Kdm
Kdw (i)
• In the worst case scenario (non-linear binding regimen, many confounding muta-
tions p −→ 1, extremely strong impact of confounders KdCKdw (i) −→ ∞) we get a false
negative prediction.
⇒ KdMKdW (i) −→ 1
For the case of epistasis involving position i, we get a different result:
We extend the example from above with an epistatic interaction of the two positions, such
that the co-occurrence of both mutations lead to a 3-fold amplification of the effect com-
pared to no epistasis. Note: Instead of using the epistasis value E introduced in Chapter
5.1.5, we denote the magnitudal epistatic effect in the following as E = e−E, i.e. the
amount of increase or decrease of the absolute effect (we will refer to that later in this
chapter).
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· E1,2 = 6. (8.11)




· Kdwt · (1+ 6)
= Kdwt · 3.5. (8.12)




· Kdwt · (1+ 2)
= Kdwt · 1.5. (8.13)







which is a vast overestimation of the true effect Kdm,wKdwt = 1.
When we investigate the effect for a mutation at position 2, we come to a similarly drastic




· Kdwt · (2+ 6)
= Kdwt · 4, (8.15)




· Kdwt · (1+ 1)
= Kdwt · 1. (8.16)







a 2-fold deviation from the true effect for a single mutation at position 2 Kdm,wKdwt = 2.
Hence, we seek to find a possibility to predict true functional and epistatic effects with the
help of DCA.
8.2 Potts Model applied to the MIME Framework
Recapitulating, MIME allows the quantification of relative effects that a certain mutation
has on a particular function in comparison to the wild type. For this, the sequence num-
bers S of the selected fraction b and the non-selected fraction u are approximated by sta-
tistically assessment. Furthermore, the method facilitates the derivation of the structural
commitment of each position. Simply put, the relative effect is calculated by the ratios
of mutant counts m vs the wild type counts w of the selected and unselected fraction, cf.
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Eq. 5.6. This relation can also be expressed by the ratio of local probabilities of mutant































(Note: This is the raw computation of the Kd, without error correction and quality filter-
ing).
This way of relations may contain transitive information, as only local frequencies are
taken into account. The frequencies are considered in isolation. To disentangle the direct
from indirect correlations, we aim to apply methods of the direct coupling analysis, which
adapts a global model for the probability distribution of sequence variants, as introduced
in Chapter 4.3. Our aim is to incorporate these inferred direct interactions to derive quan-
titative measures for mutational effects.
Instead of using the local frequencies of nucleotides, we fit the maximum entropy model















for the wild type sequence σwt containing no mutation and mutated sequences σmi with
only one mutation m at position i
P(σwt) = P(σ | σi = w ∀ i) and (8.19)
P(σmi) = P(σ | σi = m, σj = w ∀ j 6= i). (8.20)
These probabilities are plugged into Equation (8.18), substituting the local frequencies, to































u(σmi )+Hu(σwt)+Hb(σmi )−Hb(σwt). (8.21)
Conveniently, for computing the relative effect with respect to the wild type sequence, the
costly partition function Z cancels out and the Hamiltonians are sufficient.
8.2.1 Gauge Fixing
As we saw in Chapter 4.3.1, the number of independent parameters in the statistical
model is given by (L2)q
2 + Lq, with a sequence length of L and q possible symbols per
site. In order to attain a unique solution, the number of parameters has to be fixed to
84 Chapter 8. Combining MIME and DCA Techniques: Accuracy Benchmark
match the number of constraints, which is (L2)(q− 1)2 + L(q− 1).
The gauge fixing can be achieved by setting all couplings and local fields for e.g. the last
symbol q to zero: hi(q) = 0 and gij(q, ∗) = gij(∗, q) = 0. The remaining parameters are
thus measured with respect to state q.
In the cases for the application to an MSA [9], the symbol "–" (insertion or deletion) is set
to zero. In our case, we do not consider indels. When the NGS reads are mapped to the
reference, indels are ignored and only position-wise nucleotide frequencies are of interest.
Instead of setting the parameters for one of the nucleotides to zero, we reformat the count
files: We reorder the counts for the nucleotides
A C G U
to
wt mut1 mut2 mut3
where the three possible mutations mut1, mut2 and mut3 are in the same order as A, C,
G and U (e.g. wt = C, mut1 = A, mut2 = G, mut3 = U).
Now, always the wild type nucleotide for each position is set to zero to achieve gauge
fixing:
hi(wt) = 0
gij(wt, ∗) = gij(∗, wt) = 0.
Since the Hamiltonian for the wild type sequence will be always zero (and thus e0 = 1),
the exponential Hamiltonian for a mutation sequence is already given in relation to the









u(σmi )+Hb(σmi ). (8.22)
8.2.2 Regularisation
Pseudocounts
The determination of couplings with mean field approximation involves the inversion of
the correlation matrix (cf. Eq. (4.41) in Chapter 4.3.2). In the case of undersampling, the
matrix is not invertible, which would lead to infinite coupling values.
The most simple way for regularisation is to add pseudo-observations to the real data. If
there is a variable which never occurs in the data set of M sequences, i.e. Si(A) = 0, one
solution would be to add an "extra" (M + 1)th observation where this variable occurs.
For the analysis of protein and RNA sequence data (MSA), this method is very popular
due to strong undersampling [9, 178]. Here, typically a prior distribution is chosen where
each symbol of Si is considered equally likely. The strength of the pseudocount is given
by a weight θ and is usually chosen according to the sample size M, e.g. θ = 1M or similar.
The amplitude θ is expected to vanish with M→ ∞.
In all published studies of DCA [9, 128, 129, 132, 141] applied to sequence families in
MSAs, conserved sequences are considered. Only functional and prevailed sequences are
analysed, which emerged and became evolutionary fixed in the population after many
generations due to selection pressure. Hence, many intermediate sequences, either not
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functional, or not as reproductive as other variants, may not be contained within the sam-
ple set, leading to a massive undersampling.
On the contrary, in MIME just one single step of evolution is conducted, and both the func-
tionally selected and unselected sequence sets are taken into consideration. Although, the
wild type RNA is mutated with a certain, small, mutation rate pmut, millions of sequences
are mutated in parallel. Since the mutagenesis procedure per site and symbol is assumed
to be independent and (at least roughly) identically Gaussian distributed, and the sample
size is very huge, we expect to have a complete sampling in terms of heterogeneity per
site and occurrence of symbol per site.
L1- and L2 Regularisation
Another way to prevent inferred coupling terms from being infinite, is the L2 regularisa-
tion term, which is added to the log-likelihood. Here, a prior probability distribution for
the couplings is considered which penalises large coupling values [178].
Since we do not have infinite couplings due to perfect sampling, i.e. all symbols per site
are observed, we do not need to take this kind of regularisation into consideration.
The L1-norm regularisation of couplings, corresponding to a Laplacian prior distribution,
produces a sparse interaction matrix [178]. Instead of small coupling values, this regular-
isation favours coupling terms that are zero and is again achieved by adding the penalty
term to the log-likelihood. This regularisation is of particular interest, if one expects a
sparse but strong interaction network. Especially for the mapping of pairwise contacts
the large coupling values are of interest.
However, we seek to quantify effects as accurate as possible, which may also involve low
interaction terms. Therefore, we refrain from regularisation in our analysis. Note, that the
absence of a ground truth complicates the choice of an optimal weight parameter for the
regularisation term.
8.2.3 Parameter Determination
In Chapter 4.3, different methods are introduced to infer the model parameters h and g.
DCA is applied on multiple sequence alignments in order to retrieve information about
direct interactions between pairs of residues. Pseudo-Likelihood-Maximisation (PLM)
has been shown to yield excelling results in comparison to other methods such as the
mean field approximation [128]. Nevertheless, PLM requires the knowledge about the
distribution of the full-length sample sequences in order to derive the pseudo-likelihood.
In MIME, however, the samples are sequenced using NGS, resulting in a massive amount
of short reads, i.e. no information about the full-length sequence frequencies. These con-
ditions do not suit the capability of PLM.
Besides, the adaption of DCA in MIME is fortunately applicable without the partition
function Z, which enormously simplifies the parameter inference. Therefore, the mean
field approximation is the most simple way to determine parameters h and g, conve-
niently using the standard MIME analysis input, i.e. the position– and pairwise nu-
cleotide frequencies fi(A) and fij(A, B).
In the naive mean field approximation, the coupling terms gMF can be inferred by invert-
ing the covariance matrix Cij(A, B) = fij(A, B)− fi(A) f j(B), as derived in Equation (4.41)
in Chapter 4.3:
gMFij (A, B) = −(C−1)ij(A, B). (8.23)
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Parameters hMF can be subsequently ascertained, derived in Equation (4.40), with









gij(A, B) fi(B). (8.24)
Adding the second order expansion of the Gibbs potential (Onsagar correction term) to
the mean field equation yields the TAP equation, as shown in Chapter 4.3.2. The coupling
terms gTAP are derived according to Equation (4.46)
gTAPij (A, B) =
√
1− 8 · fi(A) f j(B)[(C−1)ij(A, B)]− 1
4 · fi(A) · f j(B) , (8.25)
as well as the parameters hTAP in Equation (4.44):



















8.3 Set up the Test Data
In our benchmark, we aim to compare the accuracy regarding the prediction of single site
effects, as well as the quantification of epistasis with the methods stated above. Therefore,
we generate a test data set in order to examine the deviation from the ground truth and
to be able to compare the precision of each method.
8.3.1 Sampling Sequence Variants
For the test data set, we simulate the whole process of mutating a certain number of se-
quences M of length L, comprising q symbols, with a mutation rate pmut, since the num-
ber of available sequences, is much lower than the number of possible sequence variants
S = qL.
Although realistic RNA data would include four nucleotides (q = 4 symbols), the sam-
pling of the data set with q = 2 (wild type and mutant) is sufficient for the test purposes
here. The number of sampled, mutated sequences is chosen to be M = 12 · 106.
We simulate the mutation process sequence by sequence, starting from the original wild
type reference. Sampling each position of each sequence with a Bernoulli experiment
would be too much computational effort. Instead, we draw the number of mutations n∗
for a sequence in the first step of the mutant sampling. The probability for n mutations is






· pnmut · (1− pmut)L−n.
Then, we uniformly draw a variant with n∗ mutations. For this, we give IDs for all possi-
ble sequence variants as follows: The wild type sequence with 0 mutations has ID 1, the
sequence with only one mutation at position 1 has ID 2, one mutation at position 2 has ID
3, etc. The sequence is drawn from the ID range comprising n∗ mutations.
We restrict the maximal number of mutations nmax. The mutation probability is quite
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small, resulting in a very low probability for large numbers of mutations per sequence,
such that we can neglect these. The expected occurrence of a certain sequence variant σ
with nσ mutations is given by E (Stotσ ) = M · pnσmut · (1− pmut)L−nσ . The expected absolute
number of a sequence variant E (Stotσ ) with nσ mutations has to be large enough in order
to segregate into the functionally selected and unselected pool.
As an example, for length L = 50 and a mutation rate of pmut = 0.01, the expected emer-
gence of a particular sequence variant with n = 4 mutations is E (Stotσ ) = 12 · 106 · 0.014 ·
(1− 0.01)46 ≈ 0.07, so not even one is expected. The expected occurrence of a variant
with n = 3 mutations is given by E (Stotσ ) = 12 · 106 · 0.013 · (1− 0.01)47 ≈ 7.48. Here, we
would consider E (Stotσ ) large enough to be accounted for. So in this case, the choice for
the maximal number of mutations would be nmax = 3.
After sampling all M sequences, we count the appearance of each sequence Stotσ and the
total frequency of a sequence f totσ =
Stotσ
M .
8.3.2 Sampling Kds and Epistasis
The absolute dissociation constant of the wild type is given by Kdwt, which we chose to be
1 for convenience. A mutation m at position i has an effect on the function with probability
pkd. As default we set Kdm(i) = Kdwt for all positions i that have no effect. If there is an
effect, it is randomly sampled from the lognormal distribution with standard deviation of
1
Kdm(i) = exp(X), with X ∼ N (0, 1). (8.27)
As mentioned in Chapter 5.1 in Equation 5.18, pairwise epistasis is given by
E(i, j) = log
(




with −∞ < E < ∞, denoting the decrease and increase of fitness. We are observing the
magnitude of how much a double mutant is increasing or lowering the effect of the two
single mutational effects. It could be denoted as the "defect epistasis" so to say, i.e. the
inverse of the fitness epistasis, now in the range of 0 < E < ∞:
E(i, j) = e−E(i,j) = Km,m(i, j)
Km,w(i, j) · Kw,m(i, j) . (8.28)
In the following, "epistatic effects" refers to this measure of magnitude.
Two position pairs i and j have epistatic effects with probability pepistasis and the effect is
also considered to be lognormal distributed, where we chose a standard deviation of 1
Ei,j = exp(X), with X ∼ N (0, 1). (8.29)
Note: also mutations without an effect can be involved in epistatic effects, if they occur
together with other mutations.
The Kd for a sequence variant is computed by multiplying the single Kds for each residue
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8.3.3 Deriving Species Frequencies in Equilibrium
Model Specification: The mass action kinetics between the different sequence variants
describing the binding competition experiment presented in Chapter 5.1.1 is given by
dSuσ = −kon,σ · Suσ · B + koff,σ · Sbσ (8.31)
dSbσ = −koff,σ · Sbσ + kon,σ · Suσ · B (8.32)
dB =∑
σ
koff,σ · Sbσ − kon,σ · Suσ · B (8.33)
where Su and Sb denote the unbound and bound concentration of sequence variant σ. B
gives the concentration of free protein, and kon and koff the respective rates of dissociation
and association. The ratio of the latter gives the dissociation constant Kd = koffkon .
In a steady state condition, the rates of change (left hand side) become zero. Solving one
















The total number of protein in the system is given by
Btot = B +∑
σ
Sbσ, (8.37)





− B = 0. (8.38)
The square of Equation (8.38) is the objective function to minimise in order to get the
number of unbound protein B in the steady state condition. The input are the sampled
sequence concentrations and Kds, and a fixed total concentration of protein in the system
Btot. After obtaining B, we can compute the amount of bound and unbound sequences Sb
and Su (Equations (8.36) and (8.35)), corresponding to read counts in the real data.
The determination of the bound fraction in Eq. (8.36) involves the Kd values, which are
real numbers, with 0 < Kd < ∞. To avoid biases due to rounding errors, and to simulate
a result close to reality, we sample the allocation for bound or unbound fraction according
to their relative frequencies. For example, if Stotσ = 80 and the calculated fraction of bound
sequences is given by Sbσ = 28.712, we draw the number of bound sequences according
the binomial distribution Sb,simσ ∼ B(80, 28.71280 ).
In our simulations, we chose a protein concentration of 2×M.
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8.3.4 Adding Noise
Since read sequencing is error prone, we simulate these errors by adding random noise.
The probability that a nucleotide at one site is incorrectly identified is given by perr. For
each read in the bound and unbound fraction of a sequence, we simulate the erroneous
nucleotide detection by drawing the number of errors from a binomial distribution
nerr ∼ B(L, perr),
and uniformly draw the positions i where the error occurs
ierr ∼ U (L).
The wrongly identified sequence ω is incremented (Su/bω = Su/bω + 1) and the number of
the original sequence σ is decreased by 1 (Su/bσ = Su/bσ − 1). Since the vast majority of
the nucleotides are in wild type configuration, this error affects in particular false positive
mutant detections.
Note: because of reasons stated above, we allow only a total number of (also wrongly
detected) mutations of nmax.
We use a sequencing error probability per site smaller than the mutation rate, e.g. for a
mutation probability of pmut ≈ 10−2 we choose perr = 10−3.
8.3.5 Output
After sampling the error, the final sequence variant counts for the bound and unbound
pools are used to count the position– and pairwise nucleotide occurrences, respectively.
Additionally, a "control experiment" with no true mutations (pmut = 0), but the same
error rate is sampled, also resulting in a bound and a unbound fraction of the wild type
sequences. For each single position and pair of positions the nucleotides are counted,
including the (wrongly appearing) mutations. This wild type data is required for the
error correction procedure in the following analysis.
The nucleotide counts of the four samples are written into count files (1d and 2d) in the
given result directory, as described in the Software Chapter 6.1.2.
The files for the mutant and wild type samples are numbered with a consecutive id in the
following way:
number sample type
1 wild type bound
2 wild type unbound
3 mutation bound
4 mutation bunound
We also save the sampled Kds and epistasis values in the result directory, in order to
compare the predictions of the different methods with the ground truth.
8.3.6 Implementation
The sampling routines are implemented in C++.
For minimising the objective function, we used a numerical L-BFGS-B solver (from https:
//github.com/PatWie/CppNumericalSolvers).
The program is called from the command line with
DCA_Benchmark <resultDir> <L> <pMut> <pError> <pKd> <pEpi>
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and requires the parameters:
resultDir (string) path to directory where the output files are saved
L (int) sequence length
pMut (float) probability per site of a sampled read to be mutated
pErr (float) probability per site of a sampled read to be contain an error
pKd (float) probability per site to have an effect on the function when mutated
pEpi (float) probability per position pair to have epistatic effects when mutated
8.4 Evalutating different Methods
The different methods for the determination of the mutational and epistatic effects are
also implemented in C++. For the inversion of the covariance matrix we used the Eigen
package. For each method, the determined single site Kds, and the epistatic effects are
respectively written into an outputfile. The script for the evaluation and for generating
the plots is implemented in R.
We compare the precision of the standard MIME method (cf. Chapter 5.1), which we
denote as "MIME" in the following, with different DCA methods based on the mean field
approximation, including the naive mean field approach ("MF"), and the TAP equation
("TAP").
We focus on the raw Kd estimation and omit the quality filtering such as the signal-to-
noise ratio. The input for all methods are the nucleotide counts written into output files,
as described in the sampling routine above. The frequencies are error corrected according
to Section 5.1.2:
Scorrm (i) = Sm(i)− κw→m(i) · Sw(i), (8.39)
with κw→m denoting the probability of falsely detecting a mutant instead of a wild type
at position i, which is derived from the additional sample set comprising no mutations,
only errors.
For the MIME approach, the single site effects are determined with the resampling proce-
dure as described in Chapter 5.1.3, using the error corrected pairwise nucleotide counts.
For the effects of the double mutants, the respective point estimate is used, also using the
2d data. The epistasis is computed according to Equation (8.28).
The error corrected frequencies are also the input for both DCA methods. First, the respec-
tive parameters h and g are calculated as described above for the "unbound" and "bound"
fractions, and used for the determination of the probabilities for the sequences comprising
one single mutation and pairs of mutations. These values are used to compute the effects
akin to the original approach, according to Equation (8.22).
The resulting Kds and epistasis values for each position/–pairs estimated by each method
are written into individual output files.
For each test setting, we conducted N = 20 sampling runs and evaluated the pooled re-
sults of all runs. We compare the absolute deviation of the relative log Kd: log(Kestimatem )−
log(Ktruem )), to have the positive and negative effects on the same scale (−∞ < log(Km) <
∞). Thus, we have the same weight of deviation increasing and decreasing the effect. The
same is done for the epistatic effect E , with log(Eestimate)− log(E true).
Furthermore, we evaluate the tendencies of the method to deviate depending on the re-
spective value, to get an idea whether the evaluated method under– or overestimates
certain effects, i.e. true value vs the respective deviation. Plotting the true value against
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the estimated value will additionally help to assess how well the predictions match the
truth and when they cause problems. For this, we also compute the coefficient of deter-
mination R2, which is the proportion of the variance in the dependent variables that is
predictable from the independent variables. In other words, R2 measures the goodness of
fit, to assess how well the values correspond to the model. The closer R2 is to 1, the better
are the predictions.
8.5 Benchmark Results
First, we investigated whether the considered sequence length L biases the prediction
accuracy for the different methods. For this, we ascertained the deviation of the esti-
mates from the true value without any single site effect or interaction, i.e. pkd = 0 and
pepistasis = 0. Consequently, Ktruem (i) = E(ij) = 1 ∀ i, j, and since we consider the devia-
tion of the log value, we assess the respective prediction deviation from zero.
We examined the outcome for different sequence lengths L ∈ {50, 75, 100}, respectively.
For all evaluations we chose a mutation rate of pmut = 0.03, and an error probability of
perr = 0.001. In Figure 8.2 it can be seen, that the deviations for single site effects log(Km)
FIGURE 8.2: Violin plots showing the absolute deviation of the estimated
single effects log(Km) from the true value for methods naive MF, stan-
dard MIME and TAP. The other parameters for the data sampling are
pkd = pepistasis = 0, pmut = 0.03, and perr = 0.001.
predicted with MIME are unaffected by the sequence length, while the deviation for MF
enhance slightly with longer sequences. A reason for this might be a growing sample
size ∑nmaxn=0 (
L
n) including more outliers. Surprisingly, the deviations from the single site
effects with TAP disperse more extremely with growing length. We therefore chose for
the further analysis length L = 50, to avoid the bias due to the sequence length for the
performance assessment for the respective scenarios.
Notably, the deviation from effects of double mutants and zero epistasis are not consid-
erably affected by the choice of L and are similar for all three methods. A representative
example is shown in Figure 8.3.
We tested the methods with different parameter settings:
The test cases included the following combinations of pkd and pepistasis:
pkd 0.2 0.8 0.0 0.0 0.5 0.8
pepistasis 0.0 0.0 0.2 0.8 0.1 0.3
In summary, we have three different scenarios:
1. Only single site effects, no epistasis
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FIGURE 8.3: Violin plot showing the absolute deviation of the estimated log
epistasis values from zero (the true value) for methods naive MF, standard
MIME and TAP. The parameters for the data sampling are
pkd = pepistasis = 0, pmut = 0.03, and perr = 0.001.
2. No single site effects, only epistasis
3. Single site effects and epistasis
In the first scenario, mutations may have an effect, however no interactions are present.
We conducted the simulations with a low probability for each mutation to have an effect
(pkd = 0.2) and with a high probability (pkd = 0.8).
In the second scenario, we constructed test cases where single mutations have no effect
(pmut = 0) unless they co-occur with certain other mutations (pepistasis = 0.2 and 0.8).
These two cases are unlikely to be observed in reality. Their purpose is to analyse the
respective prediction behaviour of each method in the presence of the particular effect,
and facilitates the interpretation of the third scenario, where we have both single site
effects and interactions, with pmut > pepistasis. We assume, that a large proportion of
the sequence would affect the function of the RNA if mutated, including being directly
involved in the respective process, and indirectly associated by providing the functional
structure. The latter concerns sites in contact, i.e. direct interactions. Since the interactions
constitute only a part of the functionally important sites, epistasis occurs less frequently.
Again, we chose a scenario with a low probabilities for effects (pkd = 0.5 and pepistasis =
0.1) and with high probabilities (pkd = 0.8 and pepistasis = 0.3).
8.5.1 Estimation of Single Site Effects
In the following, we will analyse the accuracy of the methods to estimate relative effects
of single mutations Km.
In Figure 8.4, the plots show the absolute difference of the log estimate from the ground
truth for each method. In general, we can observe that the qualitative characteristics of
the distribution of differences are retained with varying effect probability (from top to
bottom). However, the absolute prediction errors grow with the number of sites that con-
fer an effect.
In all three scenarios, the error distribution for the standard MIME method centres around
zero, but comprises a larger deviation from zero in comparison to the MF method when
epistatic occur. On the contrary, the naive mean field approach shows a slight overesti-
mation of the values when strong epistasis is involved, though the predictions deviate
more when actual single site effects are present. The results for the TAP equation behaves
similar to MF, yet, is prone to overestimation in all scenarios. Especially noticeable in the
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(A) pkd = 0.2, pepistasis = 0. (B) pkd = 0, pepistasis = 0.2. (C) pkd = 0.5, pepistasis = 0.1.
(D) pkd = 0.8, pepistasis = 0. (E) pkd = 0, pepistasis = 0.8. (F) pkd = 0.8, pepistasis = 0.3.
FIGURE 8.4: Violin plots showing the absolute difference of the prediction
for single site effects (log(Kestim )) from the true values (log(Ktruem )) for MF,
standard MIME and TAP.
scenario involving only epistasis, where all differences are above zero. This implies, that
negative effects on function (log(Km) > 0) are overestimated, and at the same time posi-
tive effects on function( log(Km) < 0) are underestimated. For the further analysis of the
single site effect estimation, we therefore omit the results for TAP.
We investigate, if the absolute differences are connected to the strength of the true value.
In Figure 8.5, we plot the deviations of the estimated single site effects log(Kestim − log(Ktruem )
depending on the effect strength log(Ktruem ) for MF and standard MIME. Here, only sce-
narios with varying single site effects can be evaluated, i.e. the cases with pkd = 0 are not
included.
Both plots show increasing positive deviations with log(Ktruem ) −→ −∞ and growing neg-
ative deviations from zero with log(Ktruem ) −→ ∞, i.e. an underestimation of the positive
and negative effects on function. Interestingly, the plot for the results with the standard
MIME approach exhibits a steeper slope in contrast to MF, i.e. more deviation with larger
effects. The MF approach, on the contrary, shows a more widespread distribution of dif-
ferences, regardless of the true effect, particularly for the case without epistasis in Fig-
ure 8.5 (C).
To evaluate, whether the deviations lead to under– or overestimation of effects, we ex-
amine the estimated value against the true value, plotted in Figure 8.6. In order to assess
how well the estimates fit to the given model, i.e. the ground truth, we additionally
compute the respective coefficient of determination R2. The plots and the coefficients of
determination (all coefficients R2 are > 99%) already suggest that the predictions of Km
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(A) pkd = 0.2, pepistasis = 0. (B) pkd = 0.5, pepistasis = 0.1.
(C) pkd = 0.8, pepistasis = 0. (D) pkd = 0.8, pepistasis = 0.3.
FIGURE 8.5: Dotplot of the true single site effect values log(Ktruem ) versus
the absolute deviation of the estimates from the truth log(Kestim )− log(Ktruem )
predicted with MF and standard MIME.
are quite accurate for both methods. However, as we apprehended in the beginning, the
predictions for standard MIME tend to underestimate positive and negative effects of mu-
tations, when pairwise interactions occur in the data (Figure 8.6 (D)). For naive mean field,
the predictions are highly precise, regardless of the involved effects.
As shown in Equation (8.22), the Hamiltonians for the bound and unbound sample have
to be constructed in order to compute the single site effects. For the sequence with one













The remaining parameters are set to zero, since the rest of the sequence is in wild type
configuration, and epistasis is only given if at least two mutations occur. In the naive
mean field approach, parameters hMF are calculated according to Equation (8.24):
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(A) pkd = 0.2, pepistasis = 0.
R2MF = 0.9975,
R2MIME = 0.9992.
(B) pkd = 0.5, pepistasis = 0.1.
R2MF = 0.9943,
R2MIME = 0.9936.
(C) pkd = 0.8, pepistasis = 0.
R2MF = 0.9948,
R2MIME = 0.9982.
(D) pkd = 0.8, pepistasis = 0.3.
R2MF = 0.9954,
R2MIME = 0.9902.
FIGURE 8.6: Dotplot of the true single site effect values log(Ktruem ) versus the
estimates log(Kestim ) of MF and standard MIME. The black dashed diagonal
shows the identity.
We noticed in the data, that for all scenarios the inferred couplings terms g were almost
always between -1 and 0, whereas parameters h have values around -3. Furthermore, the
frequency of the mutation fi(A) is comparatively small, due to low mutation rate. Hence,
the second term of the equation, although summing up over all L-1 positions, is very
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which corresponds to the Equation 8.18, i.e. the standard MIME evaluation for single site
effects. Although the second term in Equation (8.24) for h is relatively small, it has an
amending effect on the prediction.
8.5.2 Estimation of Epistatic Effects
We performed the analogous analysis as seen above for the epistasis estimates.
A first impression of the performance of the three methods MF, MIME and TAP is given in
the violin plots of the absolute deviation of the estimates log(Eesti) from the true epistasis
values log(E true) in Figure 8.7.
(A) pkd = 0.2, pepistasis = 0. (B) pkd = 0, pepistasis = 0.2. (C) pkd = 0.5, pepistasis = 0.1.
(D) pkd = 0.8, pepistasis = 0. (E) pkd = 0, pepistasis = 0.8. (F) pkd = 0.8, pepistasis = 0.3.
FIGURE 8.7: Violin plots showing the absolute difference of the predictions
for epistasis (Eij) from the true values (both log) for MF, standard MIME
and TAP.
We can notice that in all scenarios the deviations from the ground truth centre around
zero. However, the mean field approaches are substantially prone to false predictions
when epistasis is involved with a slight tendency of underestimation, whereas the stan-
dard MIME method shows elevated biases with more frequent occurrence of single mu-
tation effects.
For the evaluations regarding epistasis values, all outcomes for MF and TAP looked
highly similar. We therefore omit the results for TAP in the following plots for clearer
comparison with the standard MIME method.
The relation of the estimate deviation to the true value are depicted in Figure 8.8. Here,
we evaluate only the scenarios with pepistasis > 0. Very unexpectedly, the predictions with
MF are predominantly underestimating the interactions, resulting in massive false neg-
atives, regardless of the amount of epistatic effects in the data. The plots with no single
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(A) pkd = 0, pepistasis = 0.2. (B) pkd = 0.5, pepistasis = 0.1.
(C) pkd = 0, pepistasis = 0.8. (D) pkd = 0.8, pepistasis = 0.3.
FIGURE 8.8: Dotplot of the true single site effect values log(E true) versus the
absolute deviation of the estimates from the truth log(Eesti)− log(E true) of
MF and standard MIME.
site effects show a clean curve, suggesting a wrong data representation for the evaluation
of the epistasis is used here. With presence of single site effects, however, the deviations
blur out.
For the standard MIME method, we can notice a quite precise determination of epistatic
effects, if pkd is zero . With occurring single site effects, the accuracy slightly drops with
large values.
In Figure 8.9 we compare the true versus the estimated log value and calculate the cor-
responding coefficient of determination R2. As we saw already in the plots before, the
standard MIME method predicts the epistatic effects accurately with certain biases with
increasing amount of single mutation effects.
In this data representation, for the case without single site effects, the estimated value pre-
dicted with MF reminds of a root- or log-like function. We plotted two different functions
on the dotplot in Figure 8.10(A), which could presumably reflect the function behind the
log MF estimates :
• f (x) = sign(x)
√|x|
• f (x) = sign(x) log(|x|+ 1)
The logarithmic function shows the closest similarity to our data, especially for negative
and small positive values. Contrarily, the root function resembles the larger positive val-
ues quite well, however strongly deviates for the rest. We transformed the MF estimates
98 Chapter 8. Combining MIME and DCA Techniques: Accuracy Benchmark
(A) pkd = 0, pepistasis = 0.2.
R2MF = 0.9687,
R2MIME = 0.9906.
(B) pkd = 0.5, pepistasis = 0.1.
R2MF = 0.9012,
R2MIME = 0.9705.
(C) pkd = 0, pepistasis = 0.8.
R2MF = 0.9801,
R2MIME = 0.9922.
(D) pkd = 0.8, pepistasis = 0.3.
R2MF = 0.913,
R2MIME = 0.9718
FIGURE 8.9: Dotplot of the true epistasis values log(E true) versus the es-
timates log(Eesti) of MF and standard MIME. The black dashed diagonal
shows the identity.
with the inverse function of the log function, resulting in a remarkably amended accor-
dance with the true values, seen in Figure 8.10(B). As expected, the largest proportion
matches quite well, with increasing deviation towards bigger positive values.
Hence, the chosen scale as derived in the beginning is not the appropriate choice for the
assessment of epistasis. If we look again at the determination of epistasic effects E with
MF, evaluated in the MIME based approach, we have
EMF(i, j) = e−EMF(i,j) = Km,m(i, j)






































(A) Plotted curves for a logarithmic func-
tion (blue) and a square root function (red).
(B) The data points for MF (red) are trans-
formed with the inverse of the logarithmic
function.
FIGURE 8.10: True epistasis values log(E true) versus the estimates log(Eesti)
of MF and standard MIME for the scenario with pkd = 0 and pepistasis = 0.8.
where the parameter h are cancelled out and the epistatic effect is derived by






In this calculation, the epistasis is given by the relation of the exponential direct coupling
terms of the unbound vs the bound samples. Nevertheless, we have seen, that this mea-
sure does not display the true epistatic effect correctly. The vast majority of the inferred
couplings for all scenarios lies between 0 and -1, regardless of the sampled effect. This
leads to an underestimation of the epistasis.
Whether the chosen methodology for the derivation of epistatic effects is unsuitable, and
an appropriate score can be found, or the coupling inference (e.g. gauge fixing, regulari-
sation) fails in the first place, needs to be explored in further analysis.
8.6 Discussion
The classical MIME approach is able to detect functionally important sites within RNA,
by quantifying effects of mutations on that function relative to the wild type at single site
resolution. Since these estimates may be confounded by effects of epistatic interactions
within the sequence, our aim was to improve the predictions by combining the MIME
approach with DCA related methods.
In our benchmark, we generated data sets with different parameters, i.e. the probabili-
ties for the sequence to comprise single site effects and epistasis. The resulting pools of
"bound" and "unbound" sequences served as input for the mentioned methods to estimate
the sampled effects. We compared the deviation from the ground truth of standard MIME
with the results of the combined approach using sequence probabilities acquired with the
naive mean field approach and the TAP equation.
TAP yielded either similar or more inaccurate results compared to the mean field method.
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For this reason, we excluded TAP for the more detailed analysis.
The estimation of effects of single mutations could indeed be improved with MF. Al-
though standard MIME already obtains very good results, MF is able to reduce the biases
for large effects.
For the inference of epistatic effects, however, both DCA methods yielded unsatisfying
results at first sight. We found a logarithmic relationship of the estimated values Eesti to
the initially sampled true value E true. However, these results are of suggestive nature and
require further investigation.
The generated test cases were sufficient for test purposes, to confirm that the integration
of a global sequence model can improve MIME predictions. In fact, we were able to as-
certain an increase in precision, which motivates us to further pursue this approach. In
subsequent studies, we are going to simulate the binding competition of longer sequences
creating an enlarged sequence space. More importantly, we are going to refine the sim-
ulation of the sequencing procedure by including the random fragmentation. Here, we
sampled and evaluated the full-length sequence, in contrast to next generation sequenc-
ing generating millions of short reads.
As soon as the approach is optimised, the aim is to undertake predictions with real se-




In this work, we addressed the determination of evolutionary constraints with focus on
the functional and structural constraints in RNA, and particular application to HIV ge-
nomic RNA.
We started with an introduction of the biology of HIV detailing all steps of the viral life
cycle. Despite the multitude of complex, interlinked processes to produce new viable viri-
ons, no cure has been found yet that eliminates a viral infection completely. Nevertheless,
effective treatment regimen exist, which disrupt essential processes of the replication cy-
cle by blocking important enzymes and receptors, or by impeding reverse transcription
with nucleoside analogues [5]. They inhibit the viral productivity and permit a nearly
unimpaired quality of living for infected people. Still, in few cases, the virus is able to es-
cape the treatment through (multi-)drug resistance mutations. Therefore, new treatment
strategies are required.
Non-coding RNAs regulate virtually all cellular processes [179], and we have seen that
the HIV gRNA plays a pivotal role in multiple mechanisms of the HIV life cycle. This cir-
cumstance suggests promising opportunities to expand the existing repertoire of antiviral
therapeutics [180–183]. Already in early studies, the hairpin structure of the HIV transac-
tivation response (TAR), facilitating the transcription of the viral DNA, was identified as a
promising target for drug-like compounds [184–186], and could be confirmed and further
developed in subsequent work [165, 187, 188].
One challenge for drug development is the determination of RNA motifs and structures
which are related to essential functions. Moreover, molecules have to be developed which
are eligible to bind to that functional element and simultaneously exhibit sufficient drug-
likeliness [7]. This means, the considered molecule has to meet certain criteria to be ap-
proved as a potential drug. This involves several physicochemical properties, including
lack of toxicity, cell– and tissue permeability, high affinity to bind the target, and high
selectivity and specificity [7]. The latter imply a detailed knowledge about motifs in gran-
ular resolution, in order to specify and assess the structural sophistication of the potential
target.
However, the regulatory landscape in the genomic RNA of HIV, together with the map-
ping of corresponding structures, requires substantial exploration as coherent mecha-
nisms and function-structure relations are still incompletely understood [155].
Regions comprising functionally important elements constrain the evolution of the gRNA.
Patterns and motifs prevail in the genetic pool of the population due to high fitness, since
only a functional genome permits a viable organism.
We presented various methods to determine these evolutionary constraints. The quite
recent direct coupling analysis (DCA) framework borrows approaches from statistical
physics, implementing a maximum-entropy model to describe the information in bio-
logical sequence data within an MSA. The model comprises parameters, which need to
be fit to derive a probability distribution of the sequence space. In most applications,
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the coupling terms were used to infer direct pairwise interactions [9, 128, 129, 132, 141].
These direct couplings can be used to qualitatively nominate residues in close proximity
and to conclude secondary– and tertiary structures. However, the data is only composed
of viable organisms. Many generations of functional selection led to the accumulation of
particularly strong and predominant variants, whereas intermediate variants are missing.
Additionally, the MSA represents the variants with the highest total fitness correspond-
ing to selective constraints, not necessarily in relation to a certain trait or function: It may
happen that a genotype which would be more advantageous for a modular function is
not or less observed, because the same genotype might be detrimental for another essen-
tial function or trait, and thus for the total fitness. Potentially valuable insights about
structure-function relations might be masked.
Furthermore, these inferred structural information may represent a conglomerate of mul-
tiple different structures: Functional RNAs are compact information carriers exhibiting
a high density of information. Often, gene segments encoding certain proteins overlap
with regulatory regions, which already makes it difficult to detect functionally important
sites. Moreover, RNAs can be multifunctional, i.e. the same regulatory region may form
diverse structure conformations for different tasks [58, 63].
In MIME [8, 11], on the contrary, a single evolutionary step is executed to define muta-
tional effects on a particular function. Copies of a reference sequence are randomly mu-
tated and segregate into functionally selected and unselected sequence pools. Mutations
which disrupt the function are expected to be less present in the selected pool relative to
the allocation ratio of the reference sequence. Hence, the method allows to quantify rela-
tive effects that each mutation has on the function. Beyond the single site effects, MIME
data can be used to estimate epistasis, including compensatory mutations: e.g. two indi-
vidual mutations disrupt the function, but the co-occurrence of the mutations restores it,
for instance by building a basepair involved in the structure.
MIME has been conducted in in vitro experiments to identify motifs within the 5′ UTR of
the HIV genome explicitly crucial for Pr55Gag binding [8]. We adapted the MIME frame-
work for in cell experiments [12], analysing two phases of the HIV replication cycle. We
were able to find three motifs involved in gRNA production and two signals which are
important for gRNA packaging. One of the motifs, mapped to the 5′ PolyA structure,
even had contradicting influence on both processes, which displays once more the com-
plex and opaque correlations of the entire HIV replication process.
We were able to show that MIME can be used for functional structure mapping not only
for fine-grained functions, but also for more sophisticated procedures in complex cell en-
vironments. Yet, we have seen, that the quantitative estimations might deviate when
epsitatic interactions are involved. For the inference of mutational effects at a certain
site, local nucleotide frequencies are used, which means effects of coupled mutation sites
might intrude the predicted outcome. We attempted to facilitate ideas from DCA, the
incorporation of a global model for the inference of sequence probabilities instead of fre-
quencies, in order to improve the predictions. For the inference of the model parameters,
we implemented the mean field approximation and its extension, the TAP equation. We
generated test data for various scenarios comprising different portions of positions and
pairs of positions which have an effect on the function when mutated. We compared
the deviation from the ground truth of the MIME predictions and the results of the DCA
methods. Indeed, we could achieve slight improvements for the determination of single
site effects, especially for large values. However, the estimation for epistasis with DCA
methods revealed unexpected behaviour. As we already discussed in the correspond-
ing chapter, the derived scoring for the epistasis is not adequate, at least in combination
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with the low order of magnitude of the inferred coupling terms. In further investiga-
tions we would like to ascertain, if a more suitable measure exists, in order to harness
the relationship of couplings of the selected and unselected fractions to correctly quantify
epistasis. Another issue might be the choice of gauge fixing. We learnt, that the same
number of independent parameters and constraints of the model can be achieved with
diverse methods of gauge fixing. In our case, we set all parameters for one of the symbols
to zero, which is convenient for the inference of sequence probabilities relative to the wild
type sequence. However, some scoring schemes using inferred couplings in existing ap-
plications are not necessarily gauge invariant [132, 189]. We would like to inspect in more
detail, if parameter inference with zero-sum gauge fixing leads to similar results, or if we
are able to improve the prediction.
For future work, we consider in silico evolution experiments, akin to the directed enzyme
evolution in vitro by Frances H. Arnold et al. [100, 190], which was honoured with a No-
bel Prize in Chemistry in 2018. The idea here is to set up a cycle of directed selection:
sequences are diversified (error-prone PCR, recombination, mutagenesis), selected by fit-
ness, where the unselected sequences are discarded, and the selected pool is again diver-
sified and the cycle starts over again, until a certain functional optimum is reached.
For our benchmark, we set up a similar approach, for the purpose of simulating a MIME
experiment: We randomly mutate a reference sequence, sample their effect and epistatic
effects on function and simulate the functional process. This functional process can be
modelled in arbitrary complexity or modularity. We could accomplish several generations
of the competitive experiment, always applied to the selected sequence fraction of the cur-
rent generation, until we reach a somewhat stable population optimised for the simulated
function. It would be interesting to evaluate and possibly optimise the performance of
various methods for the determination of evolutionary constraints. The generated data
underlies a genuine ground truth and we would be able to ascertain the behaviour of var-
ious algorithms under certain conditions.
An additional prospective aim is further detailed mapping of various RNA structures
on specific functions in HIV or other organisms. Another approach to infer hints about
structural information, which was not introduced in detail in this work, is the so called
chemical Probing or Selective 2′-Hydroxyl Acylation and Primer Extension (SHAPE) ex-
periment [191, 192]. The method allows to determine residues in folded RNA sequences,
which are accessible to chemical probing, and as a consequence presumably unpaired.
On the contrary, the knowledge of which positions are interacting is lacking here, and
complicates a subsequent structure inference. As we have discussed earlier, RNAs often
exhibit rich landscapes with multiple structures. It still remains a challenge to disentangle
the true structure ensembles and associate the correct biological function. Combining the
structural constraints of the chemical probing with the functional mapping and epistasis
information of the MIME approach may lead to accurate assignment of structure-function





Seit ihrem Beginn vor etwa 30 Jahren, konnte die weltweite Epidemie von HIV noch im-
mer nicht aufgehalten werden und kostete seither mehrere Millionen Menschenleben.
Der Virus greift das Immunsystem seines Wirtes an. Bleibt eine HIV Infektion unbe-
handelt, führt sie zu schweren opportunistischen Erkrankungen, bis hin zu AIDS. In
dieser Phase ist das Immunsystem bereits schwer geschädigt und führt rasch zum Tode
der infizierten Person. Glücklicherweise ist die Zahl der jährlichen Neuinfektionen auf-
grund umfassender Aufklärungskampagnen und effektiver Behandlungsmöglichkeiten
rückläufig. Zwar wurde bis heute keine wirksame Impfung oder vollkommene Heilung
entdeckt, jedoch können infizierte Personen mit Hilfe von antiretroviralen Therapien eine
nahezu durchschnittliche Lebenserwartung erreichen. Allerdings ist HIV, bedingt durch
hohe Mutationsrate und schnellem Replikationszyklus, ein besonders anpassungsfähiger
Virus, was ihm ermöglicht, Resistenzen gegen Medikamente auszubilden. Die Situation
wird besonders kritisch, wenn sich Multiresistenzen entwickeln. Die Entdeckung neuer
Behandlungsstrategien ist daher von dringender Notwendigkeit.
RNAs enthalten neben Genregionen, in denen essentielle Proteine kodiert sind, eine Viel-
zahl regulatorischer Elemente und funktionaler Strukturen, die die meisten biologischen
Prozesse beeinflussen. Eine Veränderung dieser Regionen durch Mutation, würde unter
Umständen zur Folge haben, dass der Organismus nicht überlebt, da lebenswichtige
Funktionen nicht ausgeführt werden können. Funtionsrelevante Motive und Strukturen
bilden sogenannte Evolutionary Constraints, also funktions- und strukturabhängige Hem-
mung von Evolution. Das macht sie zu vielversprecheneden Angriffspunkten für neue
Wirkstoffe. Dies setzt detailliertes Wissen über die regulatorischen Mechanismen und
notwendigen Strukturen vorraus, die an lebenswichtigen Prozessen des HIV Zyklus be-
teiligt sind. Jedoch sind die genauen Abläufe und Zusammenhänge dieser Mechanismen
nicht ausgiebig erforscht.
In der vorliegenden Arbeit behandeln wir Techniken zur Bestimmung von Evolutionary
Constraints, im Kontext von genomischer RNA in HIV. Wir erläutern unterschiedliche
Herangehensweisen, um qualitative und quantitative Rückschlüsse auf Evolutionary Con-
straints zu ziehen. Hauptaugenmerk legen wir dabei auf die beiden Methoden Direct
Coupling Analysis (DCA) und Mutational Interference Mapping Experiment (MIME).
Basierend auf Letzterer, präsentieren wir Software zur Vorhersage von funktionalen Ele-
menten in RNA. Des Weiteren haben wir das MIME Framework für in cellulo Experimente
adaptiert. Dabei konnten wir regulatorische Motive im 5′ untranslatierten Bereich des
HIV-1 Genoms detektieren, welche sowohl wichtig für die Produktion viraler RNA in
Zellen, als auch für die Integration des viralen Genoms in neu entstehende Viren sind.
Zum Schluss haben wir das Ziel verfolgt, die Vorhersage funktionaler Regionen in MIME
zu verbessern, in dem wir an DCA angelehnte Methoden einbeziehen. Dazu führen wir
einen Benchmark mit verschiedenen Szenarien durch. Wir generieren Daten mit unter-
schiedlich vielen Mutationseffekten, welche die Funktion der RNA einschränken, sowie
paarweiser Epistasis (Evolutionary Constraints). Tatächlich konnten wir für einige Fälle
Verbesserungen feststellen. Dies sind jedoch vorerst vorläufige Ergebnisse, die uns aber
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